

A mutation in APP protects against Alzheimer's disease

Nature

488, 96-99

DOI: [10.1038/nature11283](https://doi.org/10.1038/nature11283)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Driving A $\beta$ into reverse. <i>Nature Reviews Neuroscience</i> , 2012, 13, 601-601.	4.9	3
4	$\beta$ -Site Amyloid Precursor Protein (APP)-cleaving Enzyme 1 (BACE1)-deficient Mice Exhibit a Close Homolog of L1 (CHL1) Loss-of-function Phenotype Involving Axon Guidance Defects. <i>Journal of Biological Chemistry</i> , 2012, 287, 38408-38425.	1.6	134
5	Are Retinoids a Promise for Alzheimer's Disease Management?. <i>Current Medicinal Chemistry</i> , 2012, 19, 6119-6125.	1.2	6
6	Clinical and Biomarker Changes in Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 2050-2052.	13.9	5
7	Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 864-866.	13.9	38
8	A protective mutation against Alzheimer disease?. <i>Communicative and Integrative Biology</i> , 2012, 5, 301-303.	0.6	5
9	The secreted Alzheimer-related amyloid precursor protein fragment has an essential role in <i>C. elegans</i> . <i>Prion</i> , 2012, 6, 433-436.	0.9	2
10	Down's syndrome and Alzheimer's disease: towards secondary prevention. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 655-656.	21.5	41
11	Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network. <i>Clinical Investigation</i> , 2012, 2, 975-984.	0.0	180
12	Exome sequencing and complex disease: practical aspects of rare variant association studies. <i>Human Molecular Genetics</i> , 2012, 21, R1-R9.	1.4	114
13	Aging, Protein Aggregation, Chaperones and Neurodegenerative Disorders: Mechanisms of Coupling and Therapeutic Opportunities. <i>Rambam Maimonides Medical Journal</i> , 2012, 3, e0021.	0.4	13
14	The Genetics of Alzheimer's Disease. <i>Scientifica</i> , 2012, 2012, 1-14.	0.6	63
16	Pharmacogenomics in clinical practice and drug development. <i>Nature Biotechnology</i> , 2012, 30, 1117-1124.	9.4	91
17	Discovery of a Novel Pharmacological and Structural Class of Gamma Secretase Modulators Derived from the Extract of <i>Actaea racemosa</i> . <i>ACS Chemical Neuroscience</i> , 2012, 3, 941-951.	1.7	58
18	Energy Intake and Exercise as Determinants of Brain Health and Vulnerability to Injury and Disease. <i>Cell Metabolism</i> , 2012, 16, 706-722.	7.2	340
19	Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2012, 287, 41245-41257.	1.6	108
20	Hypothesis-driven genomics pays off. <i>Genome Biology</i> , 2012, 13, .	3.8	0
21	HSV, axonal transport and Alzheimer's disease: <i>in vitro</i> and <i>in vivo</i> evidence for causal relationships. <i>Future Virology</i> , 2012, 7, 885-899.	0.9	48

#	ARTICLE	IF	CITATIONS
22	Intraneuronal $\beta$ -amyloid and its interactions with proteins and subcellular organelles. Electrophoresis, 2012, 33, 3608-3616.	1.3	23
23	The genetics and neuropathology of neurodegenerative disorders: perspectives and implications for research and clinical practice. Acta Neuropathologica, 2012, 124, 297-303.	3.9	12
24	Genetics of Alzheimer's Disease. Archives of Medical Research, 2012, 43, 622-631.	1.5	104
25	Mild Cognitive Impairment: A Subset of Minor Neurocognitive Disorder?. American Journal of Geriatric Psychiatry, 2012, 20, 821-826.	0.6	18
26	Synthesis optimization of pittsburgh compound B by the captive solvent method. , 2012, , .		1
27	Next frontiers in the genetic epidemiology of Alzheimer's disease. European Journal of Epidemiology, 2012, 27, 831-836.	2.5	4
28	"The Search for Treatments and Cures for Alzheimer's Disease. ACS Medicinal Chemistry Letters, 2012, 3, 862-866.	1.3	13
29	Prions: A Piece of the Puzzle?. Science, 2012, 337, 1172-1172.	6.0	36
30	Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis. Translational Neurodegeneration, 2012, 1, 18.	3.6	94
31	Current status of vaccination therapies in Alzheimer's disease. Journal of Neurochemistry, 2012, 123, 647-651.	2.1	14
32	Active DNA $\beta$ 242 vaccination as immunotherapy for Alzheimer disease. Translational Neuroscience, 2012, 3, 307-313.	0.7	20
33	A protective mutation. Nature, 2012, 488, 38-39.	13.7	20
34	Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 71-77.	1.8	24
36	Strongly interacting photons. Nature, 2012, 488, 39-40.	13.7	7
37	Caspase-9 mediates synaptic plasticity and memory deficits of Danish dementia knock-in mice: caspase-9 inhibition provides therapeutic protection. Molecular Neurodegeneration, 2012, 7, 60.	4.4	19
38	BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and $\beta$ -amyloid production in Alzheimer's disease. Molecular Neurodegeneration, 2012, 7, 52.	4.4	131
39	Sex and gonadal hormones in mouse models of Alzheimer's disease: what is relevant to the human condition?. Biology of Sex Differences, 2012, 3, 24.	1.8	45
40	Galactic Cosmic Radiation Leads to Cognitive Impairment and Increased $\beta$ 242 Plaque Accumulation in a Mouse Model of Alzheimer's Disease. PLoS ONE, 2012, 7, e53275.	1.1	171

#	ARTICLE	IF	CITATIONS
41	Gene mutation defends against Alzheimer's disease. <i>Nature</i> , 2012, 487, 153-153.	13.7	23
42	The role of amyloidogenic protein oligomerization in neurodegenerative disease. <i>Journal of Molecular Medicine</i> , 2013, 91, 653-664.	1.7	35
43	Genetic Determinants of Osteoporosis. , 2013, , 563-604.		1
44	AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different In Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice. <i>Journal of Neuroscience</i> , 2013, 33, 10075-10084.	1.7	39
45	Validating therapeutic targets through human genetics. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 581-594.	21.5	548
46	Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology. <i>JAMA Neurology</i> , 2013, 70, 1150.	4.5	143
47	Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. <i>Progress in Neurobiology</i> , 2013, 108, 21-43.	2.8	499
48	Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine. <i>BMC Medicine</i> , 2013, 11, 81.	2.3	40
49	Amyloid- $\beta$ protein (A $\beta$ ) Glu11 is the major $\beta$ -secretase site of $\beta$ -site amyloid- $\beta$ precursor protein-cleaving enzyme 1 (BACE1), and shifting the cleavage site to A $\beta$ Asp1 contributes to Alzheimer pathogenesis. <i>European Journal of Neuroscience</i> , 2013, 37, 1962-1969.	1.2	68
50	Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story. <i>Current Opinion in Chemical Biology</i> , 2013, 17, 320-328.	2.8	56
51	A $\beta$ PP-Selective BACE Inhibitors (ASBI): Novel Class of Therapeutic Agents for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 343-355.	1.2	19
52	BACE1 as a Therapeutic Target in Alzheimer's Disease: Rationale and Current Status. <i>Drugs and Aging</i> , 2013, 30, 755-764.	1.3	46
53	The therapeutics of Alzheimer's disease: Where we stand and where we are heading. <i>Annals of Neurology</i> , 2013, 74, 328-336.	2.8	101
54	Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer A $\beta$ Oligomer Bound to Cellular Prion Protein. <i>Neuron</i> , 2013, 79, 887-902.	3.8	485
55	A quantitative analysis of spontaneous isoaspartate formation from N-terminal asparaginyl and aspartyl residues. <i>Amino Acids</i> , 2013, 44, 1205-1214.	1.2	13
56	FDG PET and the genetics of dementia. <i>Clinical and Translational Imaging</i> , 2013, 1, 235-246.	1.1	2
57	Constitutive $\beta$ - and $\gamma$ -secretase cleavages of the amyloid precursor protein are partially coupled in neurons, but not in frequently used cell lines. <i>Neurobiology of Disease</i> , 2013, 49, 137-147.	2.1	58
58	Absence of A673T amyloid- $\beta$ precursor protein variant in Alzheimer's disease and other neurological diseases. <i>Neurobiology of Aging</i> , 2013, 34, 2441.e7-2441.e8.	1.5	24

#	ARTICLE	IF	CITATIONS
59	A Paired RNAi and RabGAP Overexpression Screen Identifies Rab11 as a Regulator of $\beta$ -Amyloid Production. <i>Cell Reports</i> , 2013, 5, 1536-1551.	2.9	120
60	A Function for EHD Family Proteins in Unidirectional Retrograde Dendritic Transport of BACE1 and Alzheimer's Disease $\beta$ Production. <i>Cell Reports</i> , 2013, 5, 1552-1563.	2.9	65
61	Hydroxyethylamine-based inhibitors of BACE1: P1-P3 macrocyclization can improve potency, selectivity, and cell activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4459-4464.	1.0	17
62	Fibrillar seeds alleviate amyloid- $\beta$ cytotoxicity by omitting formation of higher-molecular-weight oligomers. <i>Biochemical and Biophysical Research Communications</i> , 2013, 439, 321-326.	1.0	13
63	SnapShot: Genetics of Alzheimer's Disease. <i>Cell</i> , 2013, 155, 968-968.e1.	13.5	86
64	Differential processing of amyloid precursor protein in brain and in peripheral blood leukocytes. <i>Neurobiology of Aging</i> , 2013, 34, 1680-1686.	1.5	14
65	Biology and Genetics of Prions Causing Neurodegeneration. <i>Annual Review of Genetics</i> , 2013, 47, 601-623.	3.2	384
66	An Involvement of Oxidative Stress in Endoplasmic Reticulum Stress and Its Associated Diseases. <i>International Journal of Molecular Sciences</i> , 2013, 14, 434-456.	1.8	324
67	Pharmacologic Inhibition of ROCK2 Suppresses Amyloid- $\beta$ Production in an Alzheimer's Disease Mouse Model. <i>Journal of Neuroscience</i> , 2013, 33, 19086-19098.	1.7	118
68	Epigenetics and Complex Traits. , 2013, , .		1
69	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. <i>Lancet Neurology</i> , The, 2013, 12, 207-216.	4.9	3,378
70	The airbag problem—a potential culprit for bench-to bedside translational efforts: relevance for Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2013, 1, 62.	2.4	31
71	Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2564-2573.	1.5	55
72	Ibuprofen Inhibits the Synaptic Failure Induced by the Amyloid- $\beta$ Peptide in Hippocampal Neurons. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 463-473.	1.2	16
73	The Senescence Hypothesis of Disease Progression in Alzheimer Disease: an Integrated Matrix of Disease Pathways for FAD and SAD. <i>Molecular Neurobiology</i> , 2013, 48, 556-570.	1.9	41
74	Caspase-6 as a novel early target in the treatment of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2013, 37, 2005-2018.	1.2	49
75	Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 11.	3.0	4
76	Advances in catheter-ablation treatment of AF. <i>Nature Reviews Cardiology</i> , 2013, 10, 63-64.	6.1	7

#	ARTICLE	IF	CITATIONS
77	Histone acetylation: molecular mnemonics on the chromatin. <i>Nature Reviews Neuroscience</i> , 2013, 14, 97-111.	4.9	512
78	2012: the year in dementia. <i>Lancet Neurology</i> , The, 2013, 12, 4-6.	4.9	7
79	Core Refinement toward Permeable $\beta$ -Secretase (BACE-1) Inhibitors with Low hERG Activity. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4181-4205.	2.9	39
80	Microglia: Scapegoat, Saboteur, or Something Else?. <i>Science</i> , 2013, 339, 156-161.	6.0	726
81	Variant of <i>TREM2</i> Associated with the Risk of Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2013, 368, 107-116.	13.9	2,085
82	Resting State Functional Connectivity in Preclinical Alzheimer's Disease. <i>Biological Psychiatry</i> , 2013, 74, 340-347.	0.7	413
83	Downregulation of $A\beta$ PP Enhances Both Calcium Content of Endoplasmic Reticulum and Acidic Stores and the Dynamics of Store Operated Calcium Channel Activity. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 407-415.	1.2	14
84	Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population. <i>Neurobiology of Aging</i> , 2013, 34, 1518.e1-1518.e3.	1.5	62
85	Mitochondrial glutathione: Features, regulation and role in disease. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 3317-3328.	1.1	160
86	Further insights into Alzheimer disease pathogenesis. <i>Nature Reviews Neurology</i> , 2013, 9, 65-66.	4.9	27
87	ADAM10 Prodomain Mutations Cause Late-Onset Alzheimer's Disease: Not Just the Latest FAD. <i>Neuron</i> , 2013, 80, 250-253.	3.8	26
88	From genetic discovery to future personalized health research. <i>New Biotechnology</i> , 2013, 30, 291-295.	2.4	24
89	Structure activity relationship studies of tricyclic bispyran sulfone $\beta$ -secretase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 844-849.	1.0	15
90	Toward the structure of presenilin/ $\beta$ -secretase and presenilin homologs. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2013, 1828, 2886-2897.	1.4	37
91	Hereditary vulnerabilities to post-operative cognitive dysfunction and dementia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 47, 128-134.	2.5	8
92	NLRP3 polymorphisms are associated with late-onset Alzheimer's disease in Han Chinese. <i>Journal of Neuroimmunology</i> , 2013, 265, 91-95.	1.1	74
93	Discrete Molecular Dynamics Study of Oligomer Formation by N-Terminally Truncated Amyloid $\beta$ -Protein. <i>Journal of Molecular Biology</i> , 2013, 425, 2260-2275.	2.0	47
94	Modeling Human Disease with Pluripotent Stem Cells: from Genome Association to Function. <i>Cell Stem Cell</i> , 2013, 12, 656-668.	5.2	176

#	ARTICLE	IF	CITATIONS
95	Does the Framingham cardiovascular disease risk score also have predictive utility for dementia death? An individual participant meta-analysis of 11,887 men and women. <i>Atherosclerosis</i> , 2013, 228, 256-258.	0.4	21
96	Headache: the changing migraine brain. <i>Lancet Neurology</i> , The, 2013, 12, 6-8.	4.9	10
97	Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 324-324.	21.5	63
98	Toward the Treatment and Prevention of Alzheimer's Disease: Rational Strategies and Recent Progress. <i>Annual Review of Medicine</i> , 2013, 64, 367-383.	5.0	89
99	Inhibition of Glycogen Synthase Kinase-3 Ameliorates $\beta$ -Amyloid Pathology and Restores Lysosomal Acidification and Mammalian Target of Rapamycin Activity in the Alzheimer Disease Mouse Model. <i>Journal of Biological Chemistry</i> , 2013, 288, 1295-1306.	1.6	193
100	Pharmacodynamics of Selective Inhibition of $\beta$ -Secretase by Avagacestat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 686-695.	1.3	59
101	BACE2 as a new diabetes target: a patent review (2010 - 2012). <i>Expert Opinion on Therapeutic Patents</i> , 2013, 23, 649-663.	2.4	19
102	The missing link in the amyloid cascade of Alzheimer's disease - Metal ions. <i>Neurochemistry International</i> , 2013, 62, 367-378.	1.9	72
103	Tau degradation: The ubiquitin-proteasome system versus the autophagy-lysosome system. <i>Progress in Neurobiology</i> , 2013, 105, 49-59.	2.8	280
104	Spirocyclic $\beta$ -Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: From Hit to Lowering of Cerebrospinal Fluid (CSF) Amyloid $\beta$ in a Higher Species. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3379-3403.	2.9	50
105	Developing Therapeutic Antibodies for Neurodegenerative Disease. <i>Neurotherapeutics</i> , 2013, 10, 459-472.	2.1	166
106	From synaptic spines to nuclear signaling: nuclear and synaptic actions of the amyloid precursor protein. <i>Journal of Neurochemistry</i> , 2013, 126, 183-190.	2.1	44
107	Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer's Disease. <i>Cell</i> , 2013, 153, 707-720.	13.5	1,505
108	Structure-Based Design of $\beta$ -Site APP Cleaving Enzyme 1 (BACE1) Inhibitors for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4156-4180.	2.9	126
109	2012: A watershed year for Alzheimer's disease research. <i>Journal of Nutrition, Health and Aging</i> , 2013, 17, 51-53.	1.5	27
110	Alzheimer's Disease Biomarkers: More Than Molecular Diagnostics. <i>Drug Development Research</i> , 2013, 74, 92-111.	1.4	6
111	Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis - but what lies beyond?. <i>Biochemical Pharmacology</i> , 2013, 85, 289-305.	2.0	181
112	Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 26.	3.0	1

#	ARTICLE	IF	CITATIONS
113	Tau pathology and neurodegeneration. <i>Lancet Neurology</i> , The, 2013, 12, 609-622.	4.9	893
114	Origins of amyloid- $\beta$ . <i>BMC Genomics</i> , 2013, 14, 290.	1.2	66
115	Development and Mechanism of $\beta$ -Secretase Modulators for Alzheimer's Disease. <i>Biochemistry</i> , 2013, 52, 3197-3216.	1.2	158
116	Rational heterodoxy: Cholesterol reformation of the amyloid doctrine. <i>Ageing Research Reviews</i> , 2013, 12, 282-288.	5.0	33
117	Can tauopathy shake the amyloid cascade hypothesis?. <i>Nature Reviews Neurology</i> , 2013, 9, 356-356.	4.9	7
118	Model Peptides Uncover the Role of the $\beta$ -Secretase Transmembrane Sequence in Metal Ion Mediated Oligomerization. <i>Journal of the American Chemical Society</i> , 2013, 135, 19354-19361.	6.6	15
119	A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. <i>Progress in Neurobiology</i> , 2013, 110, 114-123.	2.8	26
120	How next-generation sequencing is transforming complex disease genetics. <i>Trends in Genetics</i> , 2013, 29, 23-30.	2.9	70
121	COPS5 (Jab1) Protein Increases $\beta$ Site Processing of Amyloid Precursor Protein and Amyloid $\beta$ Peptide Generation by Stabilizing RanBP9 Protein Levels. <i>Journal of Biological Chemistry</i> , 2013, 288, 26668-26677.	1.6	19
122	Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 547-658.	1.2	21
123	The Arctic A $\beta$ PP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated A $\beta$ . <i>Acta Neuropathologica Communications</i> , 2013, 1, 60.	2.4	38
124	Editorial (Progress of "Current Alzheimer Research" and Future Direction). <i>Current Alzheimer Research</i> , 2013, 10, 1-3.	0.7	3
125	Immunological Aspects and Anti-Amyloid Strategy for Alzheimer's Dementia. <i>Arhiv Za Higijenu Rada I Toksikologiju</i> , 2013, 64, 603-608.	0.4	2
126	Improving the Accuracy and Efficiency of Identity-by-Descent Detection in Population Data. <i>Genetics</i> , 2013, 194, 459-471.	1.2	536
127	An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment. <i>American Journal of Neuroradiology</i> , 2013, 34, 2075-2082.	1.2	24
128	Clinical, Biological, and Imaging Features of Monogenic Alzheimer's Disease. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	27
129	Genetic Architecture of Vitamin B12 and Folate Levels Uncovered Applying Deeply Sequenced Large Datasets. <i>PLoS Genetics</i> , 2013, 9, e1003530.	1.5	112
130	Assessing association between protein truncating variants and quantitative traits. <i>Bioinformatics</i> , 2013, 29, 2419-2426.	1.8	12



#	ARTICLE	IF	CITATIONS
131	A Profile of Residents in Prairie Nursing Homes. Canadian Journal on Aging, 2013, 32, 223-231.	0.6	31
132	Structure-activity relationship of memapsin 2: implications on physiological functions and Alzheimer's disease. Acta Biochimica Et Biophysica Sinica, 2013, 45, 613-621.	0.9	2
133	Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease. Expert Opinion on Therapeutic Targets, 2013, 17, 781-794.	1.5	34
134	Targeting ubiquilin-1 in Alzheimer's disease. Expert Opinion on Therapeutic Targets, 2013, 17, 795-810.	1.5	13
135	New Genes and New Insights from Old Genes. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 358-371.	0.4	15
136	In search of low-frequency and rare variants affecting complex traits. Human Molecular Genetics, 2013, 22, R16-R21.	1.4	70
138	Increased in Vivo Amyloid- $\beta$ 242 Production, Exchange, and Loss in Presenilin Mutation Carriers. Science Translational Medicine, 2013, 5, 189ra77.	5.8	196
139	Epigenome-Wide Association Studies: Potential Insights into Human Disease. , 2013, , 287-317.		3
140	Genetics of Alzheimer's Disease. BioMed Research International, 2013, 2013, 1-13.	0.9	75
141	Advantageous Uses of Mass Spectrometry for the Quantification of Proteins. International Journal of Proteomics, 2013, 2013, 1-6.	2.0	24
142	Advances in the identification of $\beta$ -secretase inhibitors. Expert Opinion on Drug Discovery, 2013, 8, 709-731.	2.5	29
143	Family history of psychosis moderates early auditory cortical response abnormalities in non-psychotic bipolar disorder. Bipolar Disorders, 2013, 15, 774-786.	1.1	18
144	Amgen punts on deCODE's genetics know-how. Nature Biotechnology, 2013, 31, 87-88.	9.4	4
145	Molecular Pathology of Alzheimer's Disease. Colloquium Series on Neurobiology of Alzheimer S Disease, 2013, 1, 1-91.	0.0	4
146	Next generation therapeutics for Alzheimer's disease. EMBO Molecular Medicine, 2013, 5, 795-798.	3.3	21
147	Disease-modifying therapy for Alzheimer's disease: Challenges and hopes. Neurology and Clinical Neuroscience, 2013, 1, 49-54.	0.2	9
148	Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases. Therapeutic Innovation and Regulatory Science, 2013, 47, 632-638.	0.8	7
149	Genetic and Nongenetic Variation Revealed for the Principal Components of Human Gene Expression. Genetics, 2013, 195, 1117-1128.	1.2	23

#	ARTICLE	IF	CITATIONS
150	Semagacestat's fall: where next for AD therapies?. <i>Nature Medicine</i> , 2013, 19, 1214-1215.	15.2	18
151	Cerebrospinal A $\beta$ <sub>1-42</sub> and A $\beta$ <sub>1-40</sub> levels as indicators of mild cognitive impairment and patients' stratification in Alzheimer's disease. <i>Translational Psychiatry</i> , 2013, 3, e281-e281.	2.4	13
152	A $\beta$ <sub>1-42</sub> Increases Amyloid- $\beta$ <sub>1-42</sub> , Lower Amyloid- $\beta$ <sub>1-38</sub> , and Do Not Alter Amyloid- $\beta$ <sub>1-40</sub> Extracellular Production in vitro: Toward a Chemical Model of Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 107-120.	1.2	18
155	Nutrition and ageing: knowledge, gaps and research priorities. <i>Proceedings of the Nutrition Society</i> , 2013, 72, 246-250.	0.4	50
156	Is Sporadic Alzheimer's Disease Associated with Diphtheria Toxin?. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 595-600.	1.2	6
157	Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease. <i>ImmunoTargets and Therapy</i> , 2013, 2013, 105.	2.7	32
158	Prevention of Alzheimer's Disease: Intervention Studies. , 0, , .		1
159	Modulators of $\beta$ -Secretase Activity Can Facilitate the Toxic Side-Effects and Pathogenesis of Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e50759.	1.1	31
160	GPR3 Stimulates A $\beta$ Production via Interactions with APP and $\beta$ -Arrestin2. <i>PLoS ONE</i> , 2013, 8, e74680.	1.1	32
161	Alzheimer's Disease: Analyzing the Missing Heritability. <i>PLoS ONE</i> , 2013, 8, e79771.	1.1	257
162	A tale of two drug targets: the evolutionary history of BACE1 and BACE2. <i>Frontiers in Genetics</i> , 2013, 4, 293.	1.1	17
163	$\beta$ -Amyloid oligomers in aging and Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 28.	1.7	54
164	Genomic and Epigenomic Insights into Nutrition and Brain Disorders. <i>Nutrients</i> , 2013, 5, 887-914.	1.7	68
165	Metal Dyshomeostasis and Inflammation in Alzheimer's and Parkinson's Diseases: Possible Impact of Environmental Exposures. <i>Oxidative Medicine and Cellular Longevity</i> , 2013, 2013, 1-19.	1.9	99
166	Emerging Therapeutic Strategies in Alzheimer's Disease. , 0, , .		1
167	Genetic Inhibition of Phosphorylation of the Translation Initiation Factor eIF2 $\beta$ Does Not Block A $\beta$ -Dependent Elevation of BACE1 and APP Levels or Reduce Amyloid Pathology in a Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e101643.	1.1	31
168	The TRiC/CCT Chaperone Is Implicated in Alzheimer's Disease Based on Patient GWAS and an RNAi Screen in A $\beta$ -Expressing <i>Caenorhabditis elegans</i> . <i>PLoS ONE</i> , 2014, 9, e102985.	1.1	34
169	APP Is Cleaved by Bace1 in Pre-Synaptic Vesicles and Establishes a Pre-Synaptic Interactome, via Its Intracellular Domain, with Molecular Complexes that Regulate Pre-Synaptic Vesicles Functions. <i>PLoS ONE</i> , 2014, 9, e108576.	1.1	54

#	ARTICLE	IF	CITATIONS
170	Clinical Genetics of Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-10.	0.9	39
171	Glutathione and mitochondria. Frontiers in Pharmacology, 2014, 5, 151.	1.6	401
172	Genomic insights into the etiology of Alzheimer's disease: a review. Advances in Genomics and Genetics, 0, , 59.	0.8	1
174	Genomics in Neurological Disorders. Genomics, Proteomics and Bioinformatics, 2014, 12, 156-163.	3.0	23
175	Biomarkers of Alzheimer's disease. , 2014, , 801-815.		0
176	The central molecular clock is robust in the face of behavioural arrhythmia in a <i>Drosophila</i> model of Alzheimer's disease. DMM Disease Models and Mechanisms, 2014, 7, 445-58.	1.2	44
178	Alzheimer's Disease Genetics. Current Behavioral Neuroscience Reports, 2014, 1, 191-196.	0.6	8
179	PLD3 is accumulated on neuritic plaques in Alzheimer's disease brains. Alzheimer's Research and Therapy, 2014, 6, 70.	3.0	37
180	Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7741-7746.	3.3	298
181	Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease. Acta Neuropathologica Communications, 2014, 2, 135.	2.4	246
182	Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments – an update for clinicians. Neurodegenerative Disease Management, 2014, 4, 363-378.	1.2	20
183	<i>N</i> -(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[ <i>e</i> ][1,3]oxazin-4-yl)-phenyl)-amides as BACE1 inhibitors: a patent evaluation of WO2013041499. Expert Opinion on Therapeutic Patents, 2014, 24, 239-242.	2.4	3
184	The Hippocampus in Neurodegenerative Disease. Frontiers of Neurology and Neuroscience, 2014, 34, 95-108.	3.0	100
185	Specific antibody binding to the APP672-699 region shifts APP processing from $\beta$ - to $\gamma$ -cleavage. Cell Death and Disease, 2014, 5, e1374-e1374.	2.7	9
186	Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics, 2014, 15, 1771-1790.	0.6	66
187	The Epidemiology and Prevention of Alzheimer's Disease and Projected Burden of Disease. , 2014, , 3-20.		0
188	Identification of rare variants in Alzheimer's disease. Frontiers in Genetics, 2014, 5, 369.	1.1	30
189	Axonal BACE1 dynamics and targeting in hippocampal neurons: a role for Rab11 GTPase. Molecular Neurodegeneration, 2014, 9, 1.	4.4	130

#	ARTICLE	IF	CITATIONS
190	An effective treatment for Alzheimer's disease must consider both amyloid and tau. Bioscience Horizons, 2014, 7, hzu002-hzu002.	0.6	28
191	Towards Small Molecules as Therapies for Alzheimer's Disease and Other Neurodegenerative Disorders. , 2014, , 199-290.		2
192	BACE1 Inhibitors: Attractive Therapeutics for Alzheimer's Disease. , 2014, , 518-546.		0
193	RNA-Seq Data Mining: Downregulation of NeuroD6 Serves as a Possible Biomarker for Alzheimer's Disease Brains. Disease Markers, 2014, 2014, 1-10.	0.6	36
194	Derailed Intraneuronal Signalling Drives Pathogenesis in Sporadic and Familial Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-14.	0.9	8
195	Genomic View of Bipolar Disorder Revealed by Whole Genome Sequencing in a Genetic Isolate. PLoS Genetics, 2014, 10, e1004229.	1.5	69
196	Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population. PLoS Genetics, 2014, 10, e1004494.	1.5	351
197	ABCC5, a Gene That Influences the Anterior Chamber Depth, Is Associated with Primary Angle Closure Glaucoma. PLoS Genetics, 2014, 10, e1004089.	1.5	68
198	Use of Caenorhabditis elegans as a model to study Alzheimer's disease and other neurodegenerative diseases. Frontiers in Genetics, 2014, 5, 279.	1.1	242
199	Unlocking truths of $\beta$ -secretase in Alzheimer's disease: what is the translational potential?. Future Neurology, 2014, 9, 419-429.	0.9	12
200	Genetic characterization of Greek population isolates reveals strong genetic drift at missense and trait-associated variants. Nature Communications, 2014, 5, 5345.	5.8	60
201	Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. Journal of Neurochemistry, 2014, 130, 4-28.	2.1	269
202	New genetic and epigenetic approaches in gerontology. Advances in Gerontology, 2014, 4, 238-246.	0.1	4
203	The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid- $\beta$ Production and Tau Hyperphosphorylation. Journal of Biological Chemistry, 2014, 289, 33927-33944.	1.6	84
204	Rare variants and autoimmune disease. Briefings in Functional Genomics, 2014, 13, 392-397.	1.3	5
205	Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 25-37.	0.7	58
206	A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. Nature Medicine, 2014, 20, 1452-1457.	15.2	116
207	8-Tetrahydropyran-2-yl Chromans: Highly Selective Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 10112-10129.	2.9	17

#	ARTICLE	IF	CITATIONS
208	Investigating the role of rare coding variability in Mendelian dementia genes ( APP , PSEN1 , PSEN2 , GRN) Tj ETQq0,0,0 rgBT /Q Overlock 1	1.5	53
209	Coding variants in TREM2 increase risk for Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 5838-5846.	1.4	263
210	Assembly of Amyloid $\beta$ -Protein Variants Containing Familial Alzheimer's Disease-Linked Amino Acid Substitutions. , 2014, , 429-442.		9
211	Amyloid- $\beta$ -directed immunotherapy for Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2014, 275, 284-295.	2.7	129
212	Failure analysis of clinical trials to test the amyloid hypothesis. <i>Annals of Neurology</i> , 2014, 76, 159-161.	2.8	14
213	Effect of Potent $\beta$ -Secretase Modulator in Human Neurons Derived From Multiple Presenilin 1-Induced Pluripotent Stem Cell Mutant Carriers. <i>JAMA Neurology</i> , 2014, 71, 1481.	4.5	84
214	Decreased CALM expression reduces A $\beta$ <sub>42</sub> to total A $\beta$ ratio through clathrin-mediated endocytosis of $\beta$ -secretase. <i>Nature Communications</i> , 2014, 5, 3386.	5.8	78
215	$\beta$ -Secretase Modulators. <i>Progress in Medicinal Chemistry</i> , 2014, 53, 101-145.	4.1	44
216	BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 89.	3.0	322
217	Triptolide treatment reduces Alzheimer's disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 1385-1395.	1.2	50
218	An Antidepressant Decreases CSF A $\beta$ Production in Healthy Individuals and in Transgenic AD Mice. <i>Science Translational Medicine</i> , 2014, 6, 236re4.	5.8	142
219	A Death Receptor 6-Amyloid Precursor Protein Pathway Regulates Synapse Density in the Mature CNS But Does Not Contribute to Alzheimer's Disease-Related Pathophysiology in Murine Models. <i>Journal of Neuroscience</i> , 2014, 34, 6425-6437.	1.7	48
220	$\beta$ -secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 165.	1.7	118
222	Communication is the key.. <i>Journal of Cell Communication and Signaling</i> , 2014, 8, 275-287.	1.8	4
223	Insulin resistance, neuroinflammation, and Alzheimer's disease. <i>Reviews in the Neurosciences</i> , 2014, 25, 509-25.	1.4	51
224	Reducing Pervasive False-Positive Identical-by-Descent Segments Detected by Large-Scale Pedigree Analysis. <i>Molecular Biology and Evolution</i> , 2014, 31, 2212-2222.	3.5	44
225	Critical analysis of the use of $\beta$ -site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer's disease. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2014, 4, 1.	0.7	7
226	Biomarkers in pharmacology and drug discovery. <i>Biochemical Pharmacology</i> , 2014, 87, 172-188.	2.0	56

#	ARTICLE	IF	CITATIONS
227	Amyloid- $\beta$ diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis. <i>Neurobiology of Aging</i> , 2014, 35, S29-S34.	1.5	124
228	Absence of A673T variant in APP gene indicates an alternative protective mechanism contributing to longevity in Chinese individuals. <i>Neurobiology of Aging</i> , 2014, 35, 935.e11-935.e12.	1.5	27
230	Genetics of dementia. <i>Lancet, The</i> , 2014, 383, 828-840.	6.3	253
231	Considering a new paradigm for Alzheimer's disease research. <i>Drug Discovery Today</i> , 2014, 19, 1114-1124.	3.2	33
232	The dendritic hypothesis for Alzheimer's disease pathophysiology. <i>Brain Research Bulletin</i> , 2014, 103, 18-28.	1.4	89
233	Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in $A\beta$ Levels In Vivo and Correlation to In Vitro Potency in Primary Cortical Neurons from Mouse and Guinea Pig. <i>Pharmaceutical Research</i> , 2014, 31, 670-683.	1.7	9
234	Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. <i>Brain Imaging and Behavior</i> , 2014, 8, 183-207.	1.1	161
235	Neurodegenerative Diseases. , 2014, , .		3
236	A mutation protective against Alzheimer's disease renders amyloid $\beta$ precursor protein incapable of mediating neurotoxicity. <i>Journal of Neurochemistry</i> , 2014, 130, 291-300.	2.1	17
237	Investigation of an amyloid precursor protein protective mutation (A673T) in a North American case-control sample of late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1779.e15-1779.e16.	1.5	28
238	iPS cells: a game changer for future medicine. <i>EMBO Journal</i> , 2014, 33, 409-417.	3.5	374
239	Calcium dysregulation, and lithium treatment to forestall Alzheimer's disease – a merging of hypotheses. <i>Cell Calcium</i> , 2014, 55, 175-181.	1.1	19
240	Pharmacological chaperones stabilize retromer to limit APP processing. <i>Nature Chemical Biology</i> , 2014, 10, 443-449.	3.9	189
241	Genetic markers for diagnosis and pathogenesis of Alzheimer's disease. <i>Gene</i> , 2014, 545, 185-193.	1.0	109
242	Understanding the cause of sporadic Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 621-630.	1.4	47
243	New Mouse Model of Alzheimer's disease. <i>ACS Chemical Neuroscience</i> , 2014, 5, 499-502.	1.7	70
244	Genome-scale neurogenetics: methodology and meaning. <i>Nature Neuroscience</i> , 2014, 17, 756-763.	7.1	82
245	The evolution of amidine-based brain penetrant BACE1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2033-2045.	1.0	138

#	ARTICLE	IF	CITATIONS
246	Revitalizing Psychiatric Therapeutics. <i>Neuropsychopharmacology</i> , 2014, 39, 220-229.	2.8	76
247	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. <i>Nature</i> , 2014, 505, 550-554.	13.7	425
248	Understanding Amyloid Fibril Nucleation and A $\beta$ Oligomer/Drug Interactions from Computer Simulations. <i>Accounts of Chemical Research</i> , 2014, 47, 603-611.	7.6	118
249	Discovery of 7-Tetrahydropyran-2-yl Chromans: $\beta$ -Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors That Reduce Amyloid $\beta$ -Protein (A $\beta$ ) in the Central Nervous System. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 878-902.	2.9	36
250	Integrating the molecular and the population approaches to dementia research to help guide the future development of appropriate therapeutics. <i>Biochemical Pharmacology</i> , 2014, 88, 652-660.	2.0	6
251	Common and low-frequency variants associated with genome-wide recombination rate. <i>Nature Genetics</i> , 2014, 46, 11-16.	9.4	116
252	Familial Alzheimer A2 V Mutation Reduces the Intrinsic Disorder and Completely Changes the Free Energy Landscape of the A $\beta$ 1-28 Monomer. <i>Journal of Physical Chemistry B</i> , 2014, 118, 501-510.	1.2	65
253	The Inside-Out Amyloid Hypothesis and Synapse Pathology in Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2014, 13, 142-146.	0.8	26
254	Disease variants in genomes of 44 centenarians. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2014, 2, 438-450.	0.6	58
255	The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials. <i>Neuron</i> , 2014, 84, 608-622.	3.8	568
256	Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice. <i>Molecular Neurodegeneration</i> , 2014, 9, 42.	4.4	114
257	Lead Optimization and Modulation of hERG Activity in a Series of Aminooxazoline Xanthene $\beta$ -Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9796-9810.	2.9	36
258	Pedigree Structure and Kinship Measurements of a Mid-Michigan Community: A New North American Population Isolate Identified. <i>Human Biology</i> , 2014, 86, 59-68.	0.4	1
259	Crown ethers attenuate aggregation of amyloid beta of Alzheimer's disease. <i>Chemical Communications</i> , 2014, 50, 15792-15795.	2.2	26
260	Genetics of Alzheimer's Disease. <i>Advances in Genetics</i> , 2014, 87, 245-294.	0.8	159
261	The Alzheimer Disease Protective Mutation A2T Modulates Kinetic and Thermodynamic Properties of Amyloid- $\beta$ (A $\beta$ ) Aggregation. <i>Journal of Biological Chemistry</i> , 2014, 289, 30977-30989.	1.6	132
262	Inhibitors of $\beta$ -Site Amyloid Precursor Protein Cleaving Enzyme (BACE1): Identification of (S)-7-(2-Fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5H-spiro[chromeno[2,3-b]pyridine-5,4-benzoxazol]-2-one (AMG-8718). <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9811-9831.	2.4	64
263	Rare and low-frequency variants in human common diseases and other complex traits. <i>Journal of Medical Genetics</i> , 2014, 51, 705-714.	1.5	29

#	ARTICLE	IF	CITATIONS
264	Molecular Mechanisms of Alzheimer Disease Protection by the A673T Allele of Amyloid Precursor Protein. <i>Journal of Biological Chemistry</i> , 2014, 289, 30990-31000.	1.6	153
265	Novel APP K724M mutation causes Chinese early-onset familial Alzheimer's disease and increases amyloid- $\beta$ <sub>42</sub> to amyloid- $\beta$ <sub>40</sub> ratio. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e1-2657.e6.	1.5	14
266	Alzheimer's Disease, Anesthesia, and Surgery: A Clinically Focused Review. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014, 28, 1609-1623.	0.6	39
267	CSF in Alzheimer's Disease. <i>Advances in Clinical Chemistry</i> , 2014, 65, 143-172.	1.8	19
268	Rare-Variant Association Analysis: Study Designs and Statistical Tests. <i>American Journal of Human Genetics</i> , 2014, 95, 5-23.	2.6	837
269	Insight into the Inhibition Effect of Acidulated Serum Albumin on Amyloid $\beta$ -Protein Fibrillogenesis and Cytotoxicity. <i>Langmuir</i> , 2014, 30, 9789-9796.	1.6	36
270	Alzheimer's disease: still a perplexing problem. <i>BMJ, The</i> , 2014, 349, g4433-g4433.	3.0	9
271	Using population isolates in genetic association studies. <i>Briefings in Functional Genomics</i> , 2014, 13, 371-377.	1.3	82
272	Human stem cell models of dementia. <i>Human Molecular Genetics</i> , 2014, 23, R35-R39.	1.4	23
273	Preventing Alzheimer's Disease. , 2014, , 33-46.		1
274	CNS Amyloid- $\beta$ , Soluble APP- $\beta$ and - $\beta$ Kinetics during BACE Inhibition. <i>Journal of Neuroscience</i> , 2014, 34, 8336-8346.	1.7	33
276	Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid- $\beta$ . <i>Alzheimer's Research and Therapy</i> , 2014, 6, 14.	3.0	30
277	Perspectives on future Alzheimer therapies: amyloid- $\beta$ protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 16.	3.0	120
279	Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. <i>Neurobiology of Disease</i> , 2014, 71, 53-61.	2.1	85
280	The Earlier the Better: Alzheimer's Prevention, Early Detection, and the Quest for Pharmacological Interventions. <i>Culture, Medicine and Psychiatry</i> , 2014, 38, 217-236.	0.7	23
281	Single App knock-in mouse models of Alzheimer's disease. <i>Nature Neuroscience</i> , 2014, 17, 661-663.	7.1	846
282	Pathways to Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2014, 275, 296-303.	2.7	159
283	The A $\beta$ clearance protein transthyretin, like neprilysin, is epigenetically regulated by the amyloid precursor protein intracellular domain. <i>Journal of Neurochemistry</i> , 2014, 130, 419-431.	2.1	64



#	ARTICLE	IF	CITATIONS
284	A novel A $\beta$ 2-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice. <i>Journal of Experimental Medicine</i> , 2014, 211, 1049-1062.	4.2	94
285	Alzheimer's Disease Genetics: From the Bench to the Clinic. <i>Neuron</i> , 2014, 83, 11-26.	3.8	396
286	Exome Sequencing: New Insights into Lipoprotein Disorders. <i>Current Cardiology Reports</i> , 2014, 16, 507.	1.3	17
287	Cerebrospinal fluid biomarkers of Alzheimer's disease. <i>Neuroscience Bulletin</i> , 2014, 30, 233-242.	1.5	16
288	Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease. <i>Neuroscience Bulletin</i> , 2014, 30, 317-330.	1.5	77
289	Late-Onset Alzheimer's Disease Genes and the Potentially Implicated Pathways. <i>Current Genetic Medicine Reports</i> , 2014, 2, 85-101.	1.9	134
290	Rare Variants and Transcriptomics in Alzheimer disease. <i>Current Genetic Medicine Reports</i> , 2014, 2, 75-84.	1.9	9
291	Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1797-1810.	0.9	50
292	Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers. <i>Trends in Molecular Medicine</i> , 2014, 20, 8-15.	3.5	35
293	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. <i>Biochemical Pharmacology</i> , 2014, 88, 426-449.	2.0	105
294	Creation of Novel Cores for $\beta$ -Secretase (BACE-1) Inhibitors: A Multiparameter Lead Generation Strategy. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 440-445.	1.3	12
295	Targeting the $\beta$ secretase BACE1 for Alzheimer's disease therapy. <i>Lancet Neurology</i> , The, 2014, 13, 319-329.	4.9	527
296	Simulation of Finnish Population History, Guided by Empirical Genetic Data, to Assess Power of Rare-Variant Tests in Finland. <i>American Journal of Human Genetics</i> , 2014, 94, 710-720.	2.6	24
297	Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 187.	1.7	63
299	Pedigree Structure and Kinship Measurements of a Mid-Michigan Community: A New North American Population Isolate Identified. <i>Human Biology</i> , 2014, 86, 59.	0.4	0
301	P2-030: INVESTIGATING THE ROLE OF CLU, PICALM, AND CR1 IN ALZHEIMER'S DISEASE. , 2014, 10, P481-P481.		0
304	Alzheimer's disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15056.	18.1	1,210
305	Activity-Dependent Neuroprotective Protein (ADNP): A Case Study for Highly Conserved Chordata-Specific Genes Shaping the Brain and Mutated in Cancer. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 57-73.	1.2	44

#	ARTICLE	IF	CITATIONS
306	Upregulation effects of Tanshinone IIA on the expressions of NeuN, Nissl body, and $\beta$ -amyloid and downregulation effects on the expressions of GFAP and NF- $\kappa$ B in the brain tissues of rat models of Alzheimer's disease. <i>NeuroReport</i> , 2015, 26, 758-766.	0.6	51
307	Lamotrigine Reduces $\beta$ -Site APP-Cleaving Enzyme 1 Protein Levels Through Induction of Autophagy. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 863-876.	1.2	25
308	The role of proteotoxic stress in vascular dysfunction in the pathogenesis of Alzheimer's disease. <i>Endoplasmic Reticulum Stress in Diseases</i> , 2015, 2, .	0.2	1
309	Models of biobanks and implications for reproductive health innovation. <i>Monash Bioethics Review</i> , 2015, 33, 238-257.	0.4	7
310	Commentary on models of biobanks and implications for reproductive health innovation. <i>Monash Bioethics Review</i> , 2015, 33, 258-264.	0.4	1
311	Multiple SNP Set Analysis for Genome-Wide Association Studies Through Bayesian Latent Variable Selection. <i>Genetic Epidemiology</i> , 2015, 39, 664-677.	0.6	19
312	The age factor in Alzheimer's disease. <i>Genome Medicine</i> , 2015, 7, 106.	3.6	271
313	The A673T mutation in the amyloid precursor protein reduces the production of $\beta$ -amyloid protein from its $\beta$ -carboxyl terminal fragment in cells. <i>Acta Neuropathologica Communications</i> , 2015, 3, 66.	2.4	19
314	A Versatile Approach to CF <sub>3</sub> -Containing $\beta$ -Pyrrolidones by Tandem Michael Addition-Cyclization: Exemplification in the Synthesis of Amidine Class BACE1 Inhibitors. <i>Chemistry - A European Journal</i> , 2015, 21, 11719-11726.	1.7	16
315	Significance of transcytosis in Alzheimer's disease: BACE1 takes the scenic route to axons. <i>BioEssays</i> , 2015, 37, 888-898.	1.2	12
316	Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?1. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 815-843.	1.2	84
317	Age and amyloid effects on human central nervous system amyloid- $\beta$ kinetics. <i>Annals of Neurology</i> , 2015, 78, 439-453.	2.8	148
318	Promising Targets for the Treatment of Neurodegenerative Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 492-501.	2.3	22
319	Development of Immunoassays for the Quantitative Assessment of Amyloid- $\beta$ in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 1091-1101.	1.2	5
320	I716F APP Mutation Associates with the Deposition of Oligomeric Pyroglutamate Amyloid- $\beta$ and $\alpha$ -Synucleinopathy with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 103-114.	1.2	13
321	Genomic Discoveries and Personalized Medicine in Neurological Diseases. <i>Pharmaceutics</i> , 2015, 7, 542-553.	2.0	13
322	Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer's disease brains. <i>ELife</i> , 2015, 4, .	2.8	114
323	Can insulin signaling pathways be targeted to transport A $\beta$ out of the brain?. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 114.	1.7	27

#	ARTICLE	IF	CITATIONS
324	The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 436.	1.8	60
325	The Maze of APP Processing in Alzheimer's Disease: Where Did We Go Wrong in Reasoning?. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 186.	1.8	35
326	Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. <i>Frontiers in Neurology</i> , 2015, 6, 142.	1.1	25
327	Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. <i>Frontiers in Neurology</i> , 2015, 6, 186.	1.1	22
328	Misframed ubiquitin and impaired protein quality control: an early event in Alzheimer's disease. <i>Frontiers in Molecular Neuroscience</i> , 2015, 8, 47.	1.4	34
329	Free Cholesterol "A Double-Edge Sword in Alzheimer Disease. , 0, , .		2
330	Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. <i>Current Alzheimer Research</i> , 2015, 12, 712-722.	0.7	134
332	Pathway-Based Analysis of Genome-Wide siRNA Screens Reveals the Regulatory Landscape of App Processing. <i>PLoS ONE</i> , 2015, 10, e0115369.	1.1	19
333	Assessing the Power of Exome Chips. <i>PLoS ONE</i> , 2015, 10, e0139642.	1.1	6
334	Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model. <i>PLoS ONE</i> , 2015, 10, e0140733.	1.1	27
335	Polygenic Analysis of Late-Onset Alzheimer's Disease from Mainland China. <i>PLoS ONE</i> , 2015, 10, e0144898.	1.1	66
336	Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2015, 12, 32-46.	0.7	255
337	Bridging the Gap between Statistical and Biological Epistasis in Alzheimer's Disease. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	26
338	Clinical and Cellular Aspects of Traumatic Brain Injury. , 2015, , 691-708.		0
339	Prion-Protein-interacting Amyloid- $\beta$ Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. <i>Journal of Biological Chemistry</i> , 2015, 290, 17415-17438.	1.6	104
340	Alzheimer Disease. , 2015, , 753-768.		6
341	Rarity of the Alzheimer Disease "Protective" APP A673T Variant in the United States. <i>JAMA Neurology</i> , 2015, 72, 209.	4.5	41
342	Systems biology of neurodegenerative diseases. <i>Integrative Biology (United Kingdom)</i> , 2015, 7, 758-775.	0.6	40

#	ARTICLE	IF	CITATIONS
343	More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. <i>Neurobiology of Aging</i> , 2015, 36, 2443.e21-2443.e26.	1.5	39
344	Molecular Genetics of Pediatric Orthopaedic Disorders. , 2015, , .		2
345	Assessing Cognitive Improvement in People with Down Syndrome: Important Considerations for Drug-Efficacy Trials. <i>Handbook of Experimental Pharmacology</i> , 2015, 228, 335-380.	0.9	8
346	Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. <i>Cell</i> , 2015, 161, 1252-1265.	13.5	135
347	A novel method for expression and purification of authentic amyloid- $\beta$ with and without 15N labels. <i>Protein Expression and Purification</i> , 2015, 113, 63-71.	0.6	11
348	The case for rejecting the amyloid cascade hypothesis. <i>Nature Neuroscience</i> , 2015, 18, 794-799.	7.1	613
349	Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. <i>Nature Neuroscience</i> , 2015, 18, 800-806.	7.1	582
350	Toxic Tau Aggregation in AD. <i>Advances in Experimental Medicine and Biology</i> , 2015, 822, 3-9.	0.8	2
351	Iron is a specific cofactor for distinct oxidation- and aggregation-dependent A $\beta$ toxicity mechanisms. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 657-67.	1.2	22
352	Protein Folding Diseases. , 2015, , 203-224.		0
353	Catabolism and Anabolism of Amyloid- $\beta$ . , 2015, , 319-339.		0
354	Tau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer Disease and Hereditary Spastic Paraplegia. <i>Molecular Neurodegeneration</i> , 2015, 10, 68.	4.4	69
355	Genetic Architecture of Complex Human Traits: What Have We Learned from Genome-Wide Association Studies?. <i>Current Genetic Medicine Reports</i> , 2015, 3, 143-150.	1.9	3
356	Inhibition of protein aggregation and amyloid formation by small molecules. <i>Current Opinion in Structural Biology</i> , 2015, 30, 50-56.	2.6	259
357	Strong Inhibition of Beta-amyloid Peptide Aggregation Realized by Two Steps Evolved Peptides. <i>Chemical Biology and Drug Design</i> , 2015, 85, 356-368.	1.5	6
358	Retinal Toxicity Induced by a Novel $\beta$ -secretase Inhibitor in the Sprague-Dawley Rat. <i>Toxicologic Pathology</i> , 2015, 43, 581-592.	0.9	36
359	An Orally Available BACE1 Inhibitor That Affords Robust CNS A $\beta$ Reduction without Cardiovascular Liabilities. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 210-215.	1.3	30
360	Therapeutic genome editing: prospects and challenges. <i>Nature Medicine</i> , 2015, 21, 121-131.	15.2	1,042

#	ARTICLE	IF	CITATIONS
361	A Food and Drug Administration-approved Asthma Therapeutic Agent Impacts Amyloid $\beta$ in the Brain in a Transgenic Model of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2015, 290, 1966-1978.	1.6	65
362	The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central $\beta$ Pharmacodynamic Responses in Mice, Dogs, and Humans. <i>Journal of Neuroscience</i> , 2015, 35, 1199-1210.	1.7	159
363	Alzheimer's Protective A2T Mutation Changes the Conformational Landscape of the $\beta$ Monomer Differently Than Does the A2V Mutation. <i>Biophysical Journal</i> , 2015, 108, 738-747.	0.2	48
364	Genetics and Underlying Pathology of Dementia. <i>Neuropsychology Review</i> , 2015, 25, 113-124.	2.5	38
365	Amyloid $\beta$ oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. <i>Acta Neuropathologica</i> , 2015, 129, 183-206.	3.9	490
366	Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. <i>Neurobiology of Aging</i> , 2015, 36, 1765.e7-1765.e16.	1.5	82
367	On the lag phase in amyloid fibril formation. <i>Physical Chemistry Chemical Physics</i> , 2015, 17, 7606-7618.	1.3	590
368	Genetic Association Between APP, ADAM10 Gene Polymorphism, and Sporadic Alzheimer's Disease in the Chinese Population. <i>Neurotoxicity Research</i> , 2015, 27, 284-291.	1.3	11
369	Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. <i>Molecular Psychiatry</i> , 2015, 20, 1588-1595.	4.1	133
370	Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2678-2702.	2.9	42
371	FGFR3 inhibition rescues established memory and synapse loss in APP transgenic mice. <i>Annals of Neurology</i> , 2015, 77, 953-971.	2.8	282
372	Altered GluN2B NMDA receptor function and synaptic plasticity during early pathology in the PS2APP mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2015, 74, 254-262.	2.1	35
373	Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled $\beta$ , tau, and $\alpha$ -synuclein. <i>Science</i> , 2015, 349, 1255-1255.	6.0	753
374	Decrease in catalytic capacity of $\beta$ -secretase can facilitate pathogenesis in sporadic and Familial Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2015, 67, 55-65.	1.0	15
375	Impact of Amyloid Precursor Protein Hydrophilic Transmembrane Residues on Amyloid-Beta Generation. <i>Biochemistry</i> , 2015, 54, 2777-2784.	1.2	14
376	Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9734-9739.	3.3	187
377	Thermodynamic Description of Beta Amyloid Formation Using Physicochemical Scales and Fractal Bioinformatic Scales. <i>ACS Chemical Neuroscience</i> , 2015, 6, 745-750.	1.7	11
378	Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3699-708.	3.3	313

#	ARTICLE	IF	CITATIONS
379	Letters from Iceland. <i>Nature Genetics</i> , 2015, 47, 425-425.	9.4	11
380	CALHM1 ion channel elicits amyloid- $\beta$ clearance by insulin-degrading enzyme in cell lines and <i>in vivo</i> in the mouse brain. <i>Journal of Cell Science</i> , 2015, 128, 2330-2338.	1.2	32
381	Structural Conversion of A $\beta$ 42 Peptides from Disordered Oligomers to U-Shape Protofilaments via Multiple Kinetic Pathways. <i>PLoS Computational Biology</i> , 2015, 11, e1004258.	1.5	41
382	The amyloid precursor protein (APP) intracellular domain regulates translation of p44, a short isoform of p53, through an IRES-dependent mechanism. <i>Neurobiology of Aging</i> , 2015, 36, 2725-2736.	1.5	18
383	COP5 Protein Overexpression Increases Amyloid Plaque Burden, Decreases Spinophilin-immunoreactive Puncta, and Exacerbates Learning and Memory Deficits in the Mouse Brain. <i>Journal of Biological Chemistry</i> , 2015, 290, 9299-9309.	1.6	12
384	Neuronal hyperactivity – A key defect in Alzheimer's disease?. <i>BioEssays</i> , 2015, 37, 624-632.	1.2	182
385	<i>Prenatal Infection.</i> , 2015, , 67-87.		0
386	Alzheimer's disease clinical trials: past failures and future opportunities. <i>Clinical Investigation</i> , 2015, 5, 297-309.	0.0	15
387	Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3223-3252.	2.9	62
388	Immunotherapeutic Approaches for Alzheimer's Disease. <i>Neuron</i> , 2015, 85, 1162-1176.	3.8	241
389	Active Immunization with DNA Vaccine Reduced Cerebral Inflammation and Improved Cognitive Ability in APP/PS1 Transgenic Mice by In Vivo Electroporation. <i>Neurochemical Research</i> , 2015, 40, 1032-1041.	1.6	4
390	Genetic Variants and Related Biomarkers in Sporadic Alzheimer's Disease. <i>Current Genetic Medicine Reports</i> , 2015, 3, 19-25.	1.9	3
391	Advances in Alzheimer's Disease Drug Development. <i>BMC Medicine</i> , 2015, 13, 62.	2.3	78
392	Synaptic dysfunction and septin protein family members in neurodegenerative diseases. <i>Molecular Neurodegeneration</i> , 2015, 10, 16.	4.4	95
393	Rare variant association studies: considerations, challenges and opportunities. <i>Genome Medicine</i> , 2015, 7, 16.	3.6	176
394	Additional mechanisms conferring genetic susceptibility to Alzheimer's disease. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 138.	1.8	27
395	Immune attack: the role of inflammation in Alzheimer disease. <i>Nature Reviews Neuroscience</i> , 2015, 16, 358-372.	4.9	1,677
396	Cognitive Enhancement. <i>Handbook of Experimental Pharmacology</i> , 2015, , .	0.9	0

#	ARTICLE	IF	CITATIONS
397	Longevity Genes. <i>Advances in Experimental Medicine and Biology</i> , 2015, , .	0.8	5
398	Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice. <i>Journal of Neuroscience</i> , 2015, 35, 6931-6936.	1.7	29
399	Exome and Whole Genome Sequencing in Aging and Longevity. <i>Advances in Experimental Medicine and Biology</i> , 2015, 847, 127-139.	0.8	5
400	The role and therapeutic targeting of $\beta$ 1, $\beta$ 2- and $\beta$ 3-secretase in Alzheimer's disease. <i>Future Science OA</i> , 2015, 1, FSO11.	0.9	75
401	Pharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions. <i>Biological Psychiatry</i> , 2015, 77, 729-739.	0.7	109
402	Cellular Functions of the Amyloid Precursor Protein from Development to Dementia. <i>Developmental Cell</i> , 2015, 32, 502-515.	3.1	191
403	Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. <i>Nature Genetics</i> , 2015, 47, 445-447.	9.4	283
404	Large-scale whole-genome sequencing of the Icelandic population. <i>Nature Genetics</i> , 2015, 47, 435-444.	9.4	663
405	An Early Folding Contact between Phe19 and Leu34 is Critical for Amyloid- $\beta$ Oligomer Toxicity. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1290-1295.	1.7	52
406	Simple approach to the synthesis of novel tricyclic BACE1 inhibitor warhead through $\beta$ -lactam opening. <i>Tetrahedron Letters</i> , 2015, 56, 4028-4030.	0.7	9
407	The triggering receptor expressed on myeloid cells 2 ( <i>TREM2</i> ) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. <i>Alzheimer's and Dementia</i> , 2015, 11, 1163-1170.	0.4	70
408	Whole-genome sequencing to understand the genetic architecture of common gene expression and biomarker phenotypes. <i>Human Molecular Genetics</i> , 2015, 24, 1504-1512.	1.4	8
409	Amyloid $\beta$ Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies. <i>Chemical Reviews</i> , 2015, 115, 3518-3563.	23.0	530
410	Oxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 1428-1441.	1.8	137
411	Gene panels and primers for next generation sequencing studies on neurodegenerative disorders. <i>Molecular and Cellular Toxicology</i> , 2015, 11, 89-143.	0.8	32
412	Strategies for Imputing and Analyzing Rare Variants in Association Studies. <i>Trends in Genetics</i> , 2015, 31, 556-563.	2.9	27
413	Protective alleles and modifier variants in human health and disease. <i>Nature Reviews Genetics</i> , 2015, 16, 689-701.	7.7	105
414	Neurodegenerative Disorders as Systemic Diseases. , 2015, , .		2

#	ARTICLE	IF	CITATIONS
415	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <i>Brain</i> , 2015, 138, 3747-3759.	3.7	170
416	<i>N</i> -(2-(Piperazin-1-yl)phenyl)arylamide Derivatives as $\beta$ -Secretase (BACE1) Inhibitors: Simple Synthesis by Ugi Four-Component Reaction and Biological Evaluation. <i>Archiv Der Pharmazie</i> , 2015, 348, 330-337.	2.1	23
417	Decision tree analysis of genetic risk for clinically heterogeneous Alzheimer's disease. <i>BMC Neurology</i> , 2015, 15, 47.	0.8	25
418	Direct Correlation of Cell Toxicity to Conformational Ensembles of Genetic $A\beta$ Variants. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1990-1996.	1.7	16
419	Amyloid $\beta$ -Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer's Disease Mutation. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1732-1740.	1.7	55
420	Japonica array: improved genotype imputation by designing a population-specific SNP array with 1070 Japanese individuals. <i>Journal of Human Genetics</i> , 2015, 60, 581-587.	1.1	120
421	Genome of the Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels. <i>Nature Communications</i> , 2015, 6, 6065.	5.8	45
422	$\beta$ -Secretase processing of APP inhibits neuronal activity in the hippocampus. <i>Nature</i> , 2015, 526, 443-447.	13.7	308
423	The keystone of Alzheimer pathogenesis might be sought in $A\beta$ physiology. <i>Neuroscience</i> , 2015, 307, 26-36.	1.1	98
424	GWAS of longitudinal amyloid accumulation on $^{18}F$ -florbetapir PET in Alzheimer's disease implicates microglial activation gene <i>IL1RAP</i> . <i>Brain</i> , 2015, 138, 3076-3088.	3.7	117
425	Drugs That Bind to $\beta$ -Synuclein: Neuroprotective or Neurotoxic?. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1930-1940.	1.7	29
426	Fundamentals of Protein Structure and Function. , 2015, , .		25
427	Proteopathies: Biological, Molecular and Clinical Perspectives. , 2015, , 139-169.		1
428	Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies. <i>Journal of Immunological Methods</i> , 2015, 424, 64-79.	0.6	15
429	The APP A673T frequency differs between Nordic countries. <i>Neurobiology of Aging</i> , 2015, 36, 2909.e1-2909.e4.	1.5	10
430	Aging Mechanisms. , 2015, , .		4
431	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 83-105.	1.4	64
432	Neuropathology and biochemistry of $A\beta$ and its aggregates in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2015, 129, 167-182.	3.9	224



#	ARTICLE	IF	CITATIONS
433	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 658-671.	0.4	173
434	Disruption of sonic hedgehog signaling in Ellis-van Creveld dwarfism confers protection against bipolar affective disorder. <i>Molecular Psychiatry</i> , 2015, 20, 1212-1218.	4.1	8
435	Combining an amyloid $\beta$ (A $\beta$ ) cleaving enzyme inhibitor with a $\gamma$ -secretase modulator results in an additive reduction of A $\beta$ production. <i>FEBS Journal</i> , 2015, 282, 65-73.	2.2	18
436	Pathogenic properties of Alzheimer's $\beta$ -amyloid identified from structure-property patient-phenotype correlations. <i>Dalton Transactions</i> , 2015, 44, 2747-2754.	1.6	12
437	The Use of Pharmacological Retromer Chaperones in Alzheimer's Disease and other Endosomal-related Disorders. <i>Neurotherapeutics</i> , 2015, 12, 12-18.	2.1	30
438	Unique molecular signatures of Alzheimer's disease amyloid $\beta$ peptide mutations and deletion during aggregate/oligomer/fibril formation. <i>Journal of Neuroscience Research</i> , 2015, 93, 410-423.	1.3	8
439	Emerging Concepts in Alzheimer's Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2015, 10, 291-319.	9.6	211
440	Alzheimer's Disease Risk Genes and Mechanisms of Disease Pathogenesis. <i>Biological Psychiatry</i> , 2015, 77, 43-51.	0.7	1,034
441	$\beta$ -amyloid Peptides and Amyloid Plaques in Alzheimer's Disease. <i>Neurotherapeutics</i> , 2015, 12, 3-11.	2.1	195
442	Quality control metrics improve repeatability and reproducibility of single-nucleotide variants derived from whole-genome sequencing. <i>Pharmacogenomics Journal</i> , 2015, 15, 298-309.	0.9	9
443	Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease. <i>Neurotherapeutics</i> , 2015, 12, 49-56.	2.1	87
444	Eph receptors: New players in Alzheimer's disease pathogenesis. <i>Neurobiology of Disease</i> , 2015, 73, 137-149.	2.1	34
445	Paths to Alzheimer's disease prevention: From modifiable risk factors to biomarker enrichment strategies. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 154-163.	1.5	50
446	PLD3 in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2015, 51, 480-486.	1.9	19
447	Role of BACE1 in Cognitive Function, from Alzheimer's Disease to Traumatic Brain Injury. , 2016, , 239-266.		0
448	Modulators of Amyloid $\beta$ -Protein (A $\beta$ ) Self-Assembly. , 2016, , 97-191.		6
449	Overview of Alzheimer's disease. , 2016, , .		0
450	Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 307-316.	0.7	15

#	ARTICLE	IF	CITATIONS
451	A Mutation in <i>DAOA</i> Modifies the Age of Onset in <i>PSEN1</i> E280A Alzheimer's Disease. <i>Neural Plasticity</i> , 2016, 2016, 1-7.	1.0	25
452	Prostate Cancer: Is It a Battle Lost to Age?. <i>Geriatrics (Switzerland)</i> , 2016, 1, 27.	0.6	11
453	Genes associated with Alzheimer's disease: an overview and current status. <i>Clinical Interventions in Aging</i> , 2016, 11, 665.	1.3	235
454	Effect of Presenilin Mutations on APP Cleavage; Insights into the Pathogenesis of FAD. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 51.	1.7	44
455	Endoplasmic Reticulum Stress and Associated ROS. <i>International Journal of Molecular Sciences</i> , 2016, 17, 327.	1.8	624
456	The MKK7 p.Glu116Lys Rare Variant Serves as a Predictor for Lung Cancer Risk and Prognosis in Chinese. <i>PLoS Genetics</i> , 2016, 12, e1005955.	1.5	14
458	Alzheimer's Disease and the Aggregation of Amyloid $\beta$ . <i>Springer Theses</i> , 2016, , 31-52.	0.0	0
459	Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies. <i>Journal of Neurochemistry</i> , 2016, 139, 224-236.	2.1	17
460	The amyloid cascade hypothesis: are we poised for success or failure?. <i>Journal of Neurochemistry</i> , 2016, 139, 237-252.	2.1	308
461	A2T and A2V $A\beta$ peptides exhibit different aggregation kinetics, primary nucleation, morphology, structure, and LTP inhibition. <i>Proteins: Structure, Function and Bioinformatics</i> , 2016, 84, 488-500.	1.5	30
462	Rhodium-Catalyzed Hydrocarboxylation of Olefins with Carbon Dioxide. <i>European Journal of Organic Chemistry</i> , 2016, 2016, 3166-3170.	1.2	81
463	Nanoscale Imaging and Characterisation of Amyloid- $\beta$ . <i>Springer Theses</i> , 2016, , .	0.0	0
464	Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 447-457.	1.2	71
465	A Method for Diagnosing Alzheimer's Disease Based on Salivary Amyloid- $\beta$ Protein 42 Levels. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1175-1182.	1.2	81
466	Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases. <i>Annual Review of Genetics</i> , 2016, 50, 329-346.	3.2	53
467	Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid- $\beta$ . <i>Scientific Reports</i> , 2016, 6, 20949.	1.6	26
468	Aspartic Proteases of Alzheimer's Disease: $\beta$ - and $\gamma$ -Secretases. , 2016, , 661-669.		0
469	Evidence For and Against a Pathogenic Role of Reduced $\beta$ -Secretase Activity in Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 781-799.	1.2	44

#	ARTICLE	IF	CITATIONS
470	Design and Enabling Development of Hydroxyethylamine-Derived BACE1 Inhibitor. ACS Symposium Series, 2016, , 137-170.	0.5	0
471	From Common to Rare Variants: The Genetic Component of Alzheimer Disease. Human Heredity, 2016, 81, 129-141.	0.4	37
472	Normal Vitamin Levels and Nutritional Indices in Alzheimer's Disease Patients with Mild Cognitive Impairment or Dementia with Normal Body Mass Indexes. Journal of Alzheimer's Disease, 2016, 55, 717-725.	1.2	17
473	Classification of Big Data With Application to Imaging Genetics. Proceedings of the IEEE, 2016, 104, 2137-2154.	16.4	21
474	Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors. BioDrugs, 2016, 30, 173-194.	2.2	36
475	New Genetic Approaches to AD: Lessons from APOE-TOMM40 Phylogenetics. Current Neurology and Neuroscience Reports, 2016, 16, 48.	2.0	28
476	Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE <sub>2</sub> Signaling in Alzheimer's Disease. ACS Chemical Neuroscience, 2016, 7, 454-463.	1.7	45
477	Genome-wide linkage analyses of non-Hispanic white families identify novel loci for familial late-onset Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 2-10.	0.4	24
478	Design and synthesis of water soluble $\beta$ -aminosulfone analogues of SCH 900229 as $\beta$ -secretase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5836-5841.	1.0	3
479	New cinnamic " N-benzylpiperidine and cinnamic " N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties. European Journal of Medicinal Chemistry, 2016, 121, 376-386.	2.6	46
480	Design and synthesis of 5-cyclopropyl substituted cyclic acylguanidine compounds as BACE1 inhibitors. Chinese Chemical Letters, 2016, 27, 1626-1629.	4.8	0
481	The Role of Amyloid- $\beta$ Oligomers in Toxicity, Propagation, and Immunotherapy. EBioMedicine, 2016, 6, 42-49.	2.7	534
482	Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A $\beta$ generation in Alzheimer's disease. Acta Neuropathologica, 2016, 132, 235-256.	3.9	193
483	<i>ABCA7</i> rare variants and Alzheimer disease risk. Neurology, 2016, 86, 2134-2137.	1.5	63
484	Specific Inhibition of $\beta$ -Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein. Cell Reports, 2016, 14, 2127-2141.	2.9	87
485	Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiology of Aging, 2016, 41, 200.e13-200.e20.	1.5	174
486	Mutation analysis of the MS4A and TREM gene clusters in a case-control Alzheimer's disease data set. Neurobiology of Aging, 2016, 42, 217.e7-217.e13.	1.5	28
487	Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 645-653.	0.4	72

#	ARTICLE	IF	CITATIONS
488	An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid $\beta^2$ Precursor Protein Signaling. <i>Journal of Biological Chemistry</i> , 2016, 291, 12282-12293.	1.6	17
489	Alzheimer's therapy targeting the $\beta^2$ -secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies. <i>Brain Research Bulletin</i> , 2016, 126, 183-198.	1.4	42
490	Genomics of Alzheimer Disease. <i>JAMA Neurology</i> , 2016, 73, 867.	4.5	105
491	Genetic and Epigenetic Architecture of Alzheimer's Dementia. <i>Current Genetic Medicine Reports</i> , 2016, 4, 7-15.	1.9	2
492	Physiological and pathological roles of the $\beta^3$ -secretase complex. <i>Brain Research Bulletin</i> , 2016, 126, 199-206.	1.4	43
493	Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. <i>Nature</i> , 2016, 533, 125-129.	13.7	738
494	SEPT8 modulates $\beta^2$ -amyloidogenic processing of APP via affecting the sorting and accumulation of BACE1. <i>Journal of Cell Science</i> , 2016, 129, 2224-38.	1.2	15
495	Mutations modifying sporadic Alzheimer's disease age of onset. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 1116-1130.	1.1	20
496	Partial loss of CALM function reduces $A\beta^{242}$ production and amyloid deposition <i>in vivo</i> . <i>Human Molecular Genetics</i> , 2016, 25, 3988-3997.	1.4	24
497	Profiling the dynamics of CSF and plasma $A\beta^2$ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 202-212.	1.8	50
498	Alternative Selection of $\beta^2$ -Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid $\beta^2$ -Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the $A\beta^2$ Sequence. <i>Journal of Biological Chemistry</i> , 2016, 291, 24041-24053.	1.6	68
499	Dietary Polyphenols as Potential Remedy for Dementia. <i>Advances in Neurobiology</i> , 2016, 12, 41-56.	1.3	5
500	NIAGADS: The NIA Genetics of Alzheimer's Disease Data Storage Site. <i>Alzheimer's and Dementia</i> , 2016, 12, 1200-1203.	0.4	24
501	Alzheimer Disease and Its Growing Epidemic. <i>Neurologic Clinics</i> , 2016, 34, 941-953.	0.8	114
502	Functions of the Alzheimer's Disease Protease BACE1 at the Synapse in the Central Nervous System. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 305-315.	1.1	48
504	Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine $\beta^2$ -Site APP Cleaving Enzyme-1 (BACE1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8593-8600.	2.9	11
505	The amyloid hypothesis of Alzheimer's disease at 25 years. <i>EMBO Molecular Medicine</i> , 2016, 8, 595-608.	3.3	4,226
506	Missing heritability of complex diseases: Enlightenment by genetic variants from intermediate phenotypes. <i>BioEssays</i> , 2016, 38, 664-673.	1.2	52

#	ARTICLE	IF	CITATIONS
507	Genome research in pre-dementia stages of Alzheimer's disease. <i>Expert Reviews in Molecular Medicine</i> , 2016, 18, e11.	1.6	13
508	The human-specific <i>CASP4</i> gene product contributes to Alzheimer-related synaptic and behavioural deficits. <i>Human Molecular Genetics</i> , 2016, 25, 4315-4327.	1.4	21
509	Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation. <i>BioMetals</i> , 2016, 29, 827-839.	1.8	56
510	Autophagy Networks in Inflammation. , 2016, , .		3
511	Novel Therapies. , 2016, , 191-219.		0
512	Cyclic cis-Locked Phospho-Dipeptides Reduce Entry of A $\beta$ into Amyloidogenic Processing Pathway. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 391-410.	1.2	6
513	AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1039-1053.	1.2	68
514	A new structural approach to genomic discovery of disease: example of adult-onset diabetes. <i>Biological Cybernetics</i> , 2016, 110, 383-391.	0.6	1
515	Genomics of Alzheimer's disease: Value of high-throughput genomic technologies to dissect its etiology. <i>Molecular and Cellular Probes</i> , 2016, 30, 397-403.	0.9	11
517	TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. <i>Neuron</i> , 2016, 91, 328-340.	3.8	643
518	New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with $\gamma$ -secretase inhibition. <i>Future Medicinal Chemistry</i> , 2016, 8, 1191-1207.	1.1	23
519	Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931) as a Site-Specific Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10435-10450.	2.9	126
520	Epigenetic and genetic components of height regulation. <i>Nature Communications</i> , 2016, 7, 13490.	5.8	52
521	Memory loss. <i>Neurology: Clinical Practice</i> , 2016, 6, 523-529.	0.8	6
522	The road to restoring neural circuits for the treatment of Alzheimer's disease. <i>Nature</i> , 2016, 539, 187-196.	13.7	426
523	Network abnormalities and interneuron dysfunction in Alzheimer disease. <i>Nature Reviews Neuroscience</i> , 2016, 17, 777-792.	4.9	685
524	Chronic Neuroinflammation Underlying Pathogenesis of Alzheimer's Disease. , 2016, , 661-671.		1
525	Increased amyloidogenic APP processing in APOE $\epsilon$ 4-negative individuals with cerebral $\beta$ -amyloidosis. <i>Nature Communications</i> , 2016, 7, 10918.	5.8	48

#	ARTICLE	IF	CITATIONS
526	2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927. Expert Opinion on Therapeutic Patents, 2016, 26, 1371-1376.	2.4	3
527	Dimerization Mechanism of Alzheimer A $\beta$ <sub>40</sub> Peptides: The High Content of Intra-peptide-Stabilized Conformations in A2V and A2T Heterozygous Dimers Retards Amyloid Fibril Formation. Journal of Physical Chemistry B, 2016, 120, 12111-12126.	1.2	38
528	Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5729-5731.	1.0	14
529	Clinical Impact of Amyloid Positron Emission Tomography—Is It Worth the Cost?. JAMA Neurology, 2016, 73, 1396.	4.5	11
530	The BACE1 inhibitor verubecestat (MK-8931) reduces CNS $\beta$ -amyloid in animal models and in Alzheimer's disease patients. Science Translational Medicine, 2016, 8, 363ra150.	5.8	352
531	AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics. Journal of Alzheimer's Disease, 2016, 50, 1109-1123.	1.2	100
532	Characterization of FRM-36143 as a new $\beta$ -secretase modulator for the potential treatment of familial Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 34.	3.0	15
533	Rare TREM2 variants associated with Alzheimer's disease display reduced cell surface expression. Acta Neuropathologica Communications, 2016, 4, 98.	2.4	46
534	A novel approach for multi-SNP GWAS and its application in Alzheimer's disease. BMC Bioinformatics, 2016, 17, 268.	1.2	12
535	A loss of function variant in CASP7 protects against Alzheimer's disease in homozygous APOE $\epsilon$ 4 allele carriers. BMC Genomics, 2016, 17, 445.	1.2	26
536	Generation and deposition of A $\beta$ <sub>243</sub> by the virtually inactive presenilin-1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 458-465.	3.3	60
537	Validation of soluble amyloid $\beta$ precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. Journal of Neurochemistry, 2016, 137, 112-121.	2.1	17
538	Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond. Lancet Neurology, The, 2016, 15, 857-868.	4.9	241
539	$\beta$ -Secretase Inhibition. , 2016, , 39-62.		2
540	Alzheimer's Disease Therapeutics Targeting Apolipoprotein E. , 2016, , 271-303.		0
541	Prospects and Challenges for Alzheimer Therapeutics. , 2016, , 605-637.		2
542	The Prion-Like Properties of Amyloid $\beta$ Assemblies: Implications for Alzheimer's Disease. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a024398.	2.9	71
543	Generation of aggregation prone N-terminally truncated amyloid $\beta$ peptides by meprin $\beta$ depends on the sequence specificity at the cleavage site. Molecular Neurodegeneration, 2016, 11, 19.	4.4	65

#	ARTICLE	IF	CITATIONS
544	Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration. <i>Journal of Biological Chemistry</i> , 2016, 291, 17209-17227.	1.6	61
545	Pathway and network-based strategies to translate genetic discoveries into effective therapies. <i>Human Molecular Genetics</i> , 2016, 25, R94-R98.	1.4	33
546	Rare variants in dementia genes and Parkinson's disease. <i>European Journal of Human Genetics</i> , 2016, 24, 1661-1662.	1.4	0
547	Ion channel regulation by $\beta$ -secretase BACE1 enzymatic and non-enzymatic effects beyond Alzheimer's disease. <i>Channels</i> , 2016, 10, 365-378.	1.5	26
548	Immunotherapy Against Amyloid- $\beta$ in Alzheimer's Disease: An Overview. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 3-17.	0.1	1
549	Active Immunization Against the Amyloid- $\beta$ Peptide. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 19-35.	0.1	0
550	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 46, 235.e1-235.e9.	1.5	37
551	Differential burden of rare protein truncating variants in Alzheimer's disease patients compared to centenarians. <i>Human Molecular Genetics</i> , 2016, 25, dww150.	1.4	10
552	The $\beta$ -Secretase Modulator, BMS-932481, Modulates A $\beta$ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 138-150.	1.3	37
553	ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease. <i>EBioMedicine</i> , 2016, 9, 278-292.	2.7	40
554	Alzheimer's disease due to loss of function: A new synthesis of the available data. <i>Progress in Neurobiology</i> , 2016, 143, 36-60.	2.8	111
555	Alzheimer's disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression. <i>Molecular Neurodegeneration</i> , 2016, 11, 5.	4.4	37
556	Suspected non-Alzheimer disease pathophysiology "concept and controversy. <i>Nature Reviews Neurology</i> , 2016, 12, 117-124.	4.9	230
557	Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain A $\beta$ Reduction in Rodents. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 271-276.	1.3	35
558	Pharmacological properties of a novel and potent $\beta$ -secretase modulator as a therapeutic option for the treatment of Alzheimer's disease. <i>Brain Research</i> , 2016, 1633, 73-86.	1.1	15
559	Defining the Genetic Architecture of Alzheimer's Disease: Where Next?. <i>Neurodegenerative Diseases</i> , 2016, 16, 6-11.	0.8	13
560	The new $\beta$ amyloid-derived peptide A $\beta$ 1-6A2V-TAT(D) prevents A $\beta$ oligomer formation and protects transgenic <i>C. elegans</i> from A $\beta$ toxicity. <i>Neurobiology of Disease</i> , 2016, 88, 75-84.	2.1	17
561	Genetics of Human Aging. , 2016, , 327-358.		0

#	ARTICLE	IF	CITATIONS
562	Long noncoding RNAs in aging and age-related diseases. <i>Ageing Research Reviews</i> , 2016, 26, 1-21.	5.0	96
563	Characterization of A $\beta$ 2 Monomers through the Convergence of Ensemble Properties among Simulations with Multiple Force Fields. <i>Journal of Physical Chemistry B</i> , 2016, 120, 259-277.	1.2	81
564	Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. <i>Nature Neuroscience</i> , 2016, 19, 55-64.	7.1	168
565	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
566	Molecular genetics of early-onset Alzheimer's disease revisited. <i>Alzheimer's and Dementia</i> , 2016, 12, 733-748.	0.4	409
567	Advances in development of fluorescent probes for detecting amyloid- $\beta$ 2 aggregates. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 719-730.	2.8	67
568	Actin dynamics and cofilin-actin rods in alzheimer disease. <i>Cytoskeleton</i> , 2016, 73, 477-497.	1.0	132
569	The 5-Lipoxygenase as modulator of Alzheimer's $\beta$ -secretase and therapeutic target. <i>Brain Research Bulletin</i> , 2016, 126, 207-212.	1.4	24
570	Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon?. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7389-7409.	2.9	118
571	BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease. <i>Trends in Neurosciences</i> , 2016, 39, 158-169.	4.2	142
572	The rise and fall of insulin signaling in Alzheimer's disease. <i>Metabolic Brain Disease</i> , 2016, 31, 497-515.	1.4	42
573	Identification of $\beta$ -sarsapogenin-aglyconed-timosaponins as novel A $\beta$ 2-lowering modulators of amyloid precursor protein processing. <i>Chemical Science</i> , 2016, 7, 3206-3214.	3.7	16
574	Single administration of a novel $\beta$ -secretase modulator ameliorates cognitive dysfunction in aged C57BL/6J mice. <i>Brain Research</i> , 2016, 1633, 52-61.	1.1	1
575	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532.	4.9	1,242
576	Endogenous APP accumulates in synapses after BACE1 inhibition. <i>Neuroscience Research</i> , 2016, 109, 9-15.	1.0	5
577	Interaction mechanism exploration of HEA derivatives as BACE1 inhibitors by in silico analysis. <i>Molecular BioSystems</i> , 2016, 12, 1151-1165.	2.9	11
578	The Amyloid $\beta$ 2 Precursor Protein and Cognitive Function in Alzheimer's Disease. , 2016, , 97-133.		2
579	Novel PSEN1 mutations (H214N and R220P) associated with familial Alzheimer's disease identified by targeted exome sequencing. <i>Neurobiology of Aging</i> , 2016, 40, 192.e7-192.e11.	1.5	15



#	ARTICLE	IF	CITATIONS
580	Structure-Based Design of an Iminoheterocyclic $\beta$ -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central $A\beta$ in Nonhuman Primates. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3231-3248.	2.9	36
581	The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases. <i>Journal of Biological Chemistry</i> , 2016, 291, 4334-4341.	1.6	61
582	$\beta$ -Amyloid pathogenesis: Chemical properties versus cellular levels. <i>Alzheimer's and Dementia</i> , 2016, 12, 184-194.	0.4	28
583	Interpretation of mushroom as a common therapeutic agent for Alzheimer's disease and cardiovascular diseases. <i>Critical Reviews in Biotechnology</i> , 2016, 36, 1131-1142.	5.1	22
584	APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer's disease. <i>Molecular Psychiatry</i> , 2016, 21, 916-924.	4.1	89
585	Suppressor Mutations for Presenilin 1 Familial Alzheimer Disease Mutants Modulate $\beta$ -Secretase Activities. <i>Journal of Biological Chemistry</i> , 2016, 291, 435-446.	1.6	16
586	Updating the Cognitive Performance Scale. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 47-55.	1.2	47
587	Therapeutic strategies for Alzheimer's disease in clinical trials. <i>Pharmacological Reports</i> , 2016, 68, 127-138.	1.5	357
588	Potential of tocotrienols in the prevention and therapy of Alzheimer's disease. <i>Journal of Nutritional Biochemistry</i> , 2016, 31, 1-9.	1.9	33
589	Alzheimer's as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks. <i>Methods in Molecular Biology</i> , 2016, 1303, 3-48.	0.4	33
590	Next Generation Sequencing in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2016, 1303, 281-297.	0.4	18
591	New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes. <i>Neurochemical Research</i> , 2016, 41, 620-630.	1.6	20
592	Why therapies for Alzheimer's disease do not work: Do we have consensus over the path to follow?. <i>Ageing Research Reviews</i> , 2016, 25, 70-84.	5.0	23
593	Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective. <i>Molecular Neurobiology</i> , 2016, 53, 4833-4864.	1.9	52
594	Interaction between variants in <i>CLU</i> and <i>MS4A4E</i> modulates Alzheimer's disease risk. <i>Alzheimer's and Dementia</i> , 2016, 12, 121-129.	0.4	18
595	The genetic landscape of Alzheimer disease: clinical implications and perspectives. <i>Genetics in Medicine</i> , 2016, 18, 421-430.	1.1	695
596	Anti-amyloid Aggregation Activity of Natural Compounds: Implications for Alzheimer's Drug Discovery. <i>Molecular Neurobiology</i> , 2016, 53, 3565-3575.	1.9	73
597	Translating Neurogenomics Into New Medicines. <i>Biological Psychiatry</i> , 2016, 79, 650-656.	0.7	12

#	ARTICLE	IF	CITATIONS
598	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. <i>Progress in Neurobiology</i> , 2017, 155, 171-193.	2.8	137
599	Molecular and cellular aspects of age-related cognitive decline and Alzheimer's disease. <i>Behavioural Brain Research</i> , 2017, 322, 191-205.	1.2	45
600	Monoaminergic neuropathology in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2017, 151, 101-138.	2.8	206
601	Brain biometals and Alzheimer's disease – boon or bane?. <i>International Journal of Neuroscience</i> , 2017, 127, 99-108.	0.8	48
602	Precise and efficient scarless genome editing in stem cells using CORRECT. <i>Nature Protocols</i> , 2017, 12, 329-354.	5.5	81
603	Prophylactic active immunization with a novel epitope vaccine improves cognitive ability by decreasing amyloid plaques and neuroinflammation in APP/PS1 transgenic mice. <i>Neuroscience Research</i> , 2017, 119, 7-14.	1.0	5
604	Gleevec shifts APP processing from a $\beta$ -cleavage to a nonamyloidogenic cleavage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1389-1394.	3.3	22
605	Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of $\beta$ -Amyloid in an Animal Model of Alzheimer's Disease. <i>Molecular Therapy</i> , 2017, 25, 153-164.	3.7	13
606	Discovery and functional prioritization of Parkinson's disease candidate genes from large-scale whole exome sequencing. <i>Genome Biology</i> , 2017, 18, 22.	3.8	96
607	Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease. <i>Advances in Biological Regulation</i> , 2017, 64, 33-38.	1.4	30
608	Comprehensive Screening for Disease Risk Variants in Early-Onset Alzheimer's Disease Genes in African Americans Identifies Novel PSEN Variants. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1215-1222.	1.2	4
609	Design, Synthesis, and Evaluation of a Novel Series of Oxadiazine Gamma Secretase Modulators for Familial Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2383-2400.	2.9	22
610	Clearance of cerebral $A\beta$ in Alzheimer's disease: reassessing the role of microglia and monocytes. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 2167-2201.	2.4	199
611	BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats. <i>Scientific Reports</i> , 2017, 7, 44249.	1.6	12
612	Systems biology approach to late-onset Alzheimer's disease genome-wide association study identifies novel candidate genes validated using brain expression data and <i>Caenorhabditis elegans</i> experiments. , 2017, 13, 1133-1142.		40
613	Flexible N-Termini of Amyloid $\beta$ -Protein Oligomers: A Link between Structure and Activity?. <i>Israel Journal of Chemistry</i> , 2017, 57, 651-664.	1.0	8
614	Rare variant of <i>MAP2K7</i> is associated with increased risk of COPD in southern and eastern Chinese. <i>Respirology</i> , 2017, 22, 691-698.	1.3	1
615	Biological basis for amyloidogenesis in Alzheimer's disease. <i>Biochemistry (Moscow)</i> , 2017, 82, 122-139.	0.7	25

#	ARTICLE	IF	CITATIONS
616	N-Terminal Hypothesis for Alzheimer's Disease. ACS Chemical Neuroscience, 2017, 8, 432-434.	1.7	29
617	Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathologica, 2017, 134, 187-205.	3.9	288
618	Preclinical models of Alzheimer's disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy. , 2017, , 115-156.		2
619	Network-assisted analysis of GWAS data identifies a functionally-relevant gene module for childhood-onset asthma. Scientific Reports, 2017, 7, 938.	1.6	14
620	Blood-Brain Barrier Transporters and Neuroinflammation: Partners in Neuroprotection and in Pathology. , 2017, , 103-151.		2
621	Genetics of common complex diseases: a view from Iceland. European Journal of Internal Medicine, 2017, 41, 3-9.	1.0	3
622	Recent Progress in Alzheimer's Disease Research, Part 2: Genetics and Epidemiology. Journal of Alzheimer's Disease, 2017, 57, 317-330.	1.2	131
623	Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease. Future Medicinal Chemistry, 2017, 9, 731-748.	1.1	11
624	Pathogenic A $\beta$ 2 versus protective A $\beta$ 2T mutation: Early stage aggregation and membrane interaction. Biophysical Chemistry, 2017, 229, 11-18.	1.5	16
625	Candidate gene analysis for Alzheimer's disease in adults with Down syndrome. Neurobiology of Aging, 2017, 56, 150-158.	1.5	22
626	Dysregulated Metabolism of the Amyloid $\beta$ Protein and Therapeutic Approaches in Alzheimer Disease. Journal of Cellular Biochemistry, 2017, 118, 4183-4190.	1.2	34
627	Development of 2-aminoxazoline 3-azaxanthene $\beta$ -amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D. MedChemComm, 2017, 8, 1196-1206.	3.5	16
628	<i>Sulfonatocalix[4]arenes Inhibit Amyloid <math>\beta</math>-Peptide Fibrillation and Reduce Amyloid Cytotoxicity. Chemistry - an Asian Journal, 2017, 12, 341-346.</i>	1.7	21
629	BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid A $\beta$ Peptides. Journal of Clinical Pharmacology, 2017, 57, 1460-1471.	1.0	44
630	Strengthening the Case for Epilepsy Drug Development: Bridging Experiences from the Alzheimer's Disease Field—An Opinion. Neurochemical Research, 2017, 42, 2099-2115.	1.6	3
631	State of Play in Alzheimer's Disease Genetics. Journal of Alzheimer's Disease, 2017, 58, 631-659.	1.2	34
632	Alzheimer's disease: How metal ions define $\beta$ -amyloid function. Coordination Chemistry Reviews, 2017, 351, 127-159.	9.5	120
633	BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis. Journal of Neuroscience, 2017, 37, 6915-6925.	1.7	81

#	ARTICLE	IF	CITATIONS
634	A Translational Systems Pharmacology Model for A $\beta$ Kinetics in Mouse, Monkey, and Human. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 666-675.	1.3	11
635	The double-edged role of copper in the fate of amyloid beta in the presence of anti-oxidants. Chemical Science, 2017, 8, 6155-6164.	3.7	20
636	Small things matter: Implications of APP intracellular domain AICD nuclear signaling in the progression and pathogenesis of Alzheimer's disease. Progress in Neurobiology, 2017, 156, 189-213.	2.8	54
637	Alzheimer's disease: where next for anti-amyloid therapies?. Brain, 2017, 140, 853-855.	3.7	57
639	High-Resolution Structures of the Amyloid- $\beta$ 1-42 Dimers from the Comparison of Four Atomistic Force Fields. Journal of Physical Chemistry B, 2017, 121, 5977-5987.	1.2	120
640	Decreased plasma $\beta$ -amyloid in the Alzheimer's disease <sc>A</sc>673<sc>T</sc> variant carriers. Annals of Neurology, 2017, 82, 128-132.	2.8	39
641	Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci. Nature Genetics, 2017, 49, 993-1004.	9.4	114
642	Is Sleep Disruption a Risk Factor for Alzheimer's Disease?. Journal of Alzheimer's Disease, 2017, 58, 993-1002.	1.2	43
643	Alzheimer Disease. Mayo Clinic Proceedings, 2017, 92, 978-994.	1.4	57
644	The impact of rare and low-frequency genetic variants in common disease. Genome Biology, 2017, 18, 77.	3.8	277
645	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA - Journal of the American Medical Association, 2017, 317, 2305.	3.8	311
646	Stem cell models of Alzheimer's disease: progress and challenges. Alzheimer's Research and Therapy, 2017, 9, 42.	3.0	112
647	Historique de la maladie d'Alzheimer: des mutations causales aux facteurs de risque g\u00e9n\u00e9tiques rares et fr\u00e9quents. Pratique Neurologique - FMC, 2017, 8, 96-105.	0.1	0
648	Paradigm shift from diagnosing patients based on common symptoms to categorizing patients into subtypes with different pathogenic mechanisms to guide treatment for Alzheimer's disease. Journal of Biochemistry, 2017, 161, 463-470.	0.9	3
650	An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. EMBO Molecular Medicine, 2017, 9, 703-715.	3.3	54
651	Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality. Journal of Medicinal Chemistry, 2017, 60, 386-402.	2.9	33
652	Genetics of $\beta$ -Amyloid Precursor Protein in Alzheimer's Disease. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024539.	2.9	118
653	Generation of Amyloid- $\beta$ Peptides by $\beta$ -Secretase. Israel Journal of Chemistry, 2017, 57, 574-585.	1.0	1

#	ARTICLE	IF	CITATIONS
654	Molecular Genetics of Neurodegenerative Dementias. Cold Spring Harbor Perspectives in Biology, 2017, 9, a023705.	2.3	51
655	Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathologica, 2017, 133, 955-966.	3.9	60
656	Genomic variants, genes, and pathways of Alzheimer's disease: An overview. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 5-26.	1.1	147
657	Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimer's Disease. Trends in Neurosciences, 2017, 40, 592-602.	4.2	114
658	Using chirality to probe the conformational dynamics and assembly of intrinsically disordered amyloid proteins. Scientific Reports, 2017, 7, 12433.	1.6	37
659	Identification of key regions and residues controlling A $\beta$ folding and assembly. Scientific Reports, 2017, 7, 12434.	1.6	20
660	M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9135-E9144.	3.3	50
661	Central and peripheral circadian clocks and their role in Alzheimer's disease. DMM Disease Models and Mechanisms, 2017, 10, 1187-1199.	1.2	44
662	Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9665-E9674.	3.3	51
663	A Framework of Real-time Wandering Management for Person with Dementia. , 2017, , .		6
664	The Pathogenic A2V Mutant Exhibits Distinct Aggregation Kinetics, Metal Site Structure, and Metal Exchange of the Cu <sup>2+</sup> -A $\beta$ Complex. Chemistry - A European Journal, 2017, 23, 13591-13595.	1.7	17
665	Genetics of Alzheimer's disease: From pathogenesis to clinical usage. Journal of Clinical Neuroscience, 2017, 45, 1-8.	0.8	33
666	Widespread brain distribution and activity following i.c.v. infusion of anti- $\beta$ -secretase (BACE1) in nonhuman primates. British Journal of Pharmacology, 2017, 174, 4173-4185.	2.7	40
667	A Toxic Conformer of A $\beta$ 242 with a Turn at 22-23 is a Novel Therapeutic Target for Alzheimer's Disease. Scientific Reports, 2017, 7, 11811.	1.6	23
668	Review: Neuropathology and behavioural features of transgenic murine models of Alzheimer's disease. Neuropathology and Applied Neurobiology, 2017, 43, 553-570.	1.8	46
669	Emergence of Alternative Structures in Amyloid Beta 1-42 Monomeric Landscape by N-terminal Hexapeptide Amyloid Inhibitors. Scientific Reports, 2017, 7, 9941.	1.6	23
670	Discovery of a Tetrahydrobenzoxazole Series of $\beta$ -Secretase Modulators. ACS Medicinal Chemistry Letters, 2017, 8, 1002-1006.	1.3	9
671	Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study. Journal of Neural Transmission, 2017, 124, 1473-1488.	1.4	15

#	ARTICLE	IF	CITATIONS
672	Amyloid $\beta$ Fibril Elongation by Monomers Involves Disorder at the Tip. <i>Journal of Chemical Theory and Computation</i> , 2017, 13, 5117-5130.	2.3	34
673	BACE inhibition-dependent repair of Alzheimer's pathophysiology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8631-8636.	3.3	93
674	Rare coding variants in <i>PLCG2</i> , <i>ABI3</i> , and <i>TREM2</i> implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
675	Contribution to Alzheimer's disease risk of rare variants in <i>TREM2</i> , <i>SORL1</i> , and <i>ABCA7</i> in 1779 cases and 1273 controls. <i>Neurobiology of Aging</i> , 2017, 59, 220.e1-220.e9.	1.5	116
676	BACE1 Deficiency Causes Abnormal Neuronal Clustering in the Dentate Gyrus. <i>Stem Cell Reports</i> , 2017, 9, 217-230.	2.3	4
677	The Alzheimer's disease-protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool. <i>Journal of Biological Chemistry</i> , 2017, 292, 15312-15320.	1.6	63
678	Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank. <i>Nature Genetics</i> , 2017, 49, 1311-1318.	9.4	56
679	Filling the void: a role for exercise-induced BDNF and brain amyloid precursor protein processing. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2017, 313, R585-R593.	0.9	25
680	Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1131-1136.	1.9	44
681	<scp>APP</scp> mouse models for Alzheimer's disease preclinical studies. <i>EMBO Journal</i> , 2017, 36, 2473-2487.	3.5	530
682	Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound $A\beta$ oligomers. <i>Molecular Biology of the Cell</i> , 2017, 28, 2623-2636.	0.9	88
683	The role of astrocytes in amyloid production and Alzheimer's disease. <i>Open Biology</i> , 2017, 7, 170228.	1.5	269
684	iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid $\beta$ Combination for Alzheimer's Disease. <i>Cell Reports</i> , 2017, 21, 2304-2312.	2.9	161
685	The $A\beta$ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. <i>Scientific Reports</i> , 2017, 7, 16275.	1.6	42
686	Genetics of Alzheimer's disease: an update. <i>Future Neurology</i> , 2017, 12, 237-247.	0.9	0
687	Better beings?. <i>Nature Biotechnology</i> , 2017, 35, 1006-1011.	9.4	7
688	Oxalate-curcumin-based probe for micro- and macroimaging of reactive oxygen species in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 12384-12389.	3.3	102
689	Modern probabilistic and statistical approaches to search for nucleotide sequence options associated with integrated diseases. <i>Russian Journal of Genetics</i> , 2017, 53, 1091-1104.	0.2	3

#	ARTICLE	IF	CITATIONS
690	A novel fluorescent probe reveals starvation controls the commitment of amyloid precursor protein to the lysosome. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 1554-1565.	1.9	19
691	Excess APP<i>O</i>-glycosylation by GalNAc-T6 decreases A $\beta$ production. <i>Journal of Biochemistry</i> , 2017, 161, 99-111.	0.9	31
692	Alzheimer's Protective Cross-Interaction between Wild-Type and A2T Variants Alters A $\beta$ <sub>42</sub> Dimer Structure. <i>ACS Chemical Neuroscience</i> , 2017, 8, 606-618.	1.7	45
693	Coarse-grained and All-atom Simulations towards the Early and Late Steps of Amyloid Fibril Formation. <i>Israel Journal of Chemistry</i> , 2017, 57, 564-573.	1.0	23
694	Leveraging human genetics to guide drug target discovery. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 352-359.	2.3	26
695	Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. <i>Progress in Biophysics and Molecular Biology</i> , 2017, 123, 16-41.	1.4	64
696	Increased Foxo3a Nuclear Translocation and Activity is an Early Neuronal Response to $\beta$ -Secretase-Mediated Processing of the Amyloid- $\beta$ Protein Precursor: Utility of an A $\beta$ PP-GAL4 Reporter Assay. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 673-688.	1.2	11
697	Implication of the APP Gene in Intellectual Abilities. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 723-735.	1.2	13
698	Perplexity of Amyloid $\beta$ -Protein Oligomer Formation: Relevance to Alzheimer's Disease. <i>World Scientific Lecture and Course Notes in Chemistry</i> , 2017, , 1-50.	0.2	4
699	Systems healthcare: a holistic paradigm for tomorrow. <i>BMC Systems Biology</i> , 2017, 11, 142.	3.0	22
700	Physiological and pathophysiological control of synaptic GluN2B-NMDA receptors by the C-terminal domain of amyloid precursor protein. <i>ELife</i> , 2017, 6, .	2.8	29
701	Molecular mechanisms of the genetic risk factors in pathogenesis of Alzheimer disease. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 180-192.	3.0	14
702	Targeting $\beta$ -Secretase (BACE) for the Treatment of Alzheimer's Disease. , 2017, , 326-383.		11
703	$\beta$ -Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View. <i>Molecules</i> , 2017, 22, 1692.	1.7	82
704	BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology. <i>Molecules</i> , 2017, 22, 1723.	1.7	89
705	Neuroprotective Actions of Dietary Choline. <i>Nutrients</i> , 2017, 9, 815.	1.7	154
706	Stop Alzheimer's before it starts. <i>Nature</i> , 2017, 547, 153-155.	13.7	189
707	A Genetic Population Isolate in The Netherlands Showing Extensive Haplotype Sharing and Long Regions of Homozygosity. <i>Genes</i> , 2017, 8, 133.	1.0	7

#	ARTICLE	IF	CITATIONS
708	Nuclear Factor-Kappa B and Alzheimer Disease, Unifying Genetic and Environmental Risk Factors from Cell to Humans. <i>Frontiers in Immunology</i> , 2017, 8, 1805.	2.2	104
709	Cross-Sectional and Longitudinal Effects of CREB1 Genotypes on Individual Differences in Memory and Executive Function: Findings from the BLSA. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 142.	1.7	10
710	The Role of Microglia in Prion Diseases: A Paradigm of Functional Diversity. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 207.	1.7	51
711	The Metalloprotease Meprin $\hat{1}^2$ Is an Alternative $\hat{1}^2$ -Secretase of APP. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 159.	1.4	43
712	Detecting At-Risk Alzheimer's Disease Cases. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 97-105.	1.2	42
713	Numerical Simulations Reveal Randomness of Cu(II) Induced $A\hat{1}^2$ Peptide Dimerization under Conditions Present in Glutamatergic Synapses. <i>PLoS ONE</i> , 2017, 12, e0170749.	1.1	19
714	Interactions within the MHC contribute to the genetic architecture of celiac disease. <i>PLoS ONE</i> , 2017, 12, e0172826.	1.1	16
715	Alzheimer's amyloid- $\hat{1}^2$ A2T variant and its N-terminal peptides inhibit amyloid- $\hat{1}^2$ fibrillization and rescue the induced cytotoxicity. <i>PLoS ONE</i> , 2017, 12, e0174561.	1.1	24
716	Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2017, 12, 82.	4.4	100
717	Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer's disease resilience. <i>Genome Medicine</i> , 2017, 9, 100.	3.6	67
718	Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 62.	3.0	62
719	Role of BACE1 in Alzheimer's synaptic function. <i>Translational Neurodegeneration</i> , 2017, 6, 23.	3.6	80
720	Mutation-induced loss of APP function causes GABAergic depletion in recessive familial Alzheimer's disease: analysis of Osaka mutation-knockin mice. <i>Acta Neuropathologica Communications</i> , 2017, 5, 59.	2.4	23
721	Rare non-coding variants are associated with plasma lipid traits in a founder population. <i>Scientific Reports</i> , 2017, 7, 16415.	1.6	31
722	From Nose to Brain: The Promise of Peptide Therapy for Alzheimer's Disease and Other Neurodegenerative Diseases. , 2017, 07, .		9
723	The past, present, and future of disease-modifying therapies for Alzheimer's disease. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2017, 93, 757-771.	1.6	31
725	The genetic landscape of Alzheimer disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 148, 395-408.	1.0	86
726	Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane. <i>Neurobiology of Disease</i> , 2018, 114, 1-16.	2.1	34



#	ARTICLE	IF	CITATIONS
727	Pathogenesis of Idiopathic Scoliosis. , 2018, , .		8
728	The Genetic Architecture of Adolescent Idiopathic Scoliosis. , 2018, , 51-74.		1
729	Weaker N-Terminal Interactions for the Protective over the Causative A $\beta$ 2 Peptide Dimer Mutants. ACS Chemical Neuroscience, 2018, 9, 1247-1253.	1.7	18
730	MicroRNA-132 is associated with the cognition improvement following voluntary exercise in SAMP8 mice. Brain Research Bulletin, 2018, 140, 80-87.	1.4	28
731	Analysis of state laws on informed consent for clinical genetic testing in the era of genomic sequencing. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2018, 178, 81-88.	0.7	15
732	Evaluation of Animal Models by Comparison with Human Late-Onset Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 9234-9250.	1.9	19
733	Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, $\beta$ -Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation. Journal of Medicinal Chemistry, 2018, 61, 4476-4504.	2.9	35
734	Toward $\beta$ -Secretase-1 Inhibitors with Improved Isoform Selectivity. Journal of Medicinal Chemistry, 2018, 61, 3491-3502.	2.9	26
735	Association between BACE1 gene polymorphisms and focal seizures in a Chinese Han population. Medicine (United States), 2018, 97, e0222.	0.4	0
736	Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine $\beta$ -amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1111-1115.	1.0	18
737	BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. Journal of Experimental Medicine, 2018, 215, 927-940.	4.2	92
738	Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead. European Journal of Medicinal Chemistry, 2018, 148, 436-452.	2.6	121
739	APLP1 is endoproteolytically cleaved by $\beta$ -secretase without previous ectodomain shedding. Scientific Reports, 2018, 8, 1916.	1.6	22
740	Adrenergic Beta Receptor Kinase 1 (Adrbk1). , 2018, , 238-238.		0
741	Amphoterin. , 2018, , 312-312.		0
742	ATP Binding Cassette Transporter A1. , 2018, , 476-476.		0
743	ACAP1. , 2018, , 75-82.		0
744	Aquaporin. , 2018, , 374-390.		1

#	ARTICLE	IF	CITATIONS
745	Role of Amyloid Precursor Protein (APP) and Its Derivatives in the Biology and Cell Fate Specification of Neural Stem Cells. <i>Molecular Neurobiology</i> , 2018, 55, 7107-7117.	1.9	56
746	Peripheral Activity and Central Substrates of BACE1: Therapeutic Implications for Alzheimer's Disease. <i>Biological Psychiatry</i> , 2018, 83, 393-394.	0.7	3
747	New Insights on the Role of Residue 673 of APP in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2018, 38, 515-517.	1.7	4
748	Adenyl Cyclase. , 2018, , 186-186.		0
749	Metabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer's disease. <i>Current Opinion in Pharmacology</i> , 2018, 38, 1-7.	1.7	29
750	Heterozygous TYROBP deletion (PLOSFIN) is not a strong risk factor for cognitive impairment. <i>Neurobiology of Aging</i> , 2018, 64, 159.e1-159.e4.	1.5	3
751	Melatonin protects against A $\beta$ -induced neurotoxicity in primary neurons via miR-132/PTEN/AKT/FOXO3a pathway. <i>BioFactors</i> , 2018, 44, 609-618.	2.6	38
752	BACE1 inhibition more effectively suppresses initiation than progression of $\beta$ -amyloid pathology. <i>Acta Neuropathologica</i> , 2018, 135, 695-710.	3.9	64
753	Reconstructing an African haploid genome from the 18th century. <i>Nature Genetics</i> , 2018, 50, 199-205.	9.4	15
754	Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 233-243.	0.8	9
755	The A $\beta$ protofibril selective antibody mAb158 prevents accumulation of A $\beta$ in astrocytes and rescues neurons from A $\beta$ -induced cell death. <i>Journal of Neuroinflammation</i> , 2018, 15, 98.	3.1	44
756	Generation of App knock-in mice reveals deletion mutations protective against Alzheimer's disease-like pathology. <i>Nature Communications</i> , 2018, 9, 1800.	5.8	33
757	Genetic Risk Factors for Complex Forms of Alzheimer's Disease. , 2018, , 51-76.		0
758	Fluorescence imaging of the interaction of amyloid beta 40 peptides with live cells and model membrane. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2018, 1860, 1609-1615.	1.4	10
759	Binding Modes of Phthalocyanines to Amyloid $\beta$ Peptide and Their Effects on Amyloid Fibril Formation. <i>Biophysical Journal</i> , 2018, 114, 1036-1045.	0.2	15
760	Packing Density of the Amyloid Precursor Protein in the Cell Membrane. <i>Biophysical Journal</i> , 2018, 114, 1128-1141.	0.2	10
761	Targeting Amyloid- $\beta$ Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid- $\beta$ Production. <i>Molecular Therapy</i> , 2018, 26, 1539-1551.	3.7	27
762	Rare human Caspase-6-R65W and Caspase-6-G66R variants identify a novel regulatory region of Caspase-6 activity. <i>Scientific Reports</i> , 2018, 8, 4428.	1.6	9

#	ARTICLE	IF	CITATIONS
763	Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3. <i>Neurobiology of Aging</i> , 2018, 66, 179.e17-179.e29.	1.5	32
764	CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 429-440.	2.3	116
765	Zinc ion rapidly induces toxic, off-pathway amyloid- $\beta^2$ oligomers distinct from amyloid- $\beta^2$ derived diffusible ligands in Alzheimer's disease. <i>Scientific Reports</i> , 2018, 8, 4772.	1.6	104
766	Looking at the Disordered Proteins through the Computational Microscope. <i>ACS Central Science</i> , 2018, 4, 534-542.	5.3	46
767	Genetic Complexity of Early-Onset Alzheimer's Disease. , 2018, , 29-50.		7
768	Translational Research in Alzheimer's and Prion Diseases. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1247-1259.	1.2	7
769	Modulation in the conformational and stability attributes of the Alzheimer's disease associated amyloid-beta mutants and their favorable stabilization by curcumin: molecular dynamics simulation analysis. <i>Journal of Biomolecular Structure and Dynamics</i> , 2018, 36, 407-422.	2.0	30
770	$\beta^2$ -Amyloid Prions and the Pathobiology of Alzheimer's Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a023507.	2.9	64
771	Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. <i>Biological Psychiatry</i> , 2018, 83, 447-455.	0.7	83
772	$\beta^2$ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2018, 109, 191-200.	2.1	57
773	Untangling Genetic Risk for Alzheimer's Disease. <i>Biological Psychiatry</i> , 2018, 83, 300-310.	0.7	160
774	lncRNAs, DNA Methylation, and the Pathobiology of Exfoliation Glaucoma. <i>Journal of Glaucoma</i> , 2018, 27, 202-209.	0.8	13
775	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 25-35.	1.4	34
776	Alzheimer's disease. <i>European Journal of Neurology</i> , 2018, 25, 59-70.	1.7	1,624
777	Amyloid- $\beta^2$ and tau complexity " towards improved biomarkers and targeted therapies. <i>Nature Reviews Neurology</i> , 2018, 14, 22-39.	4.9	303
778	Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease. <i>Molecular Psychiatry</i> , 2018, 23, 81-93.	4.1	74
779	eHealth provides a novel opportunity to exploit the advantages of the Nordic countries in psychiatric genetic research, building on the public health care system, biobanks, and registries. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 625-629.	1.1	12
780	Modulation of $\beta^3$ - and $\beta^2$ -Secretases as Early Prevention Against Alzheimer's Disease. <i>Biological Psychiatry</i> , 2018, 83, 320-327.	0.7	54

#	ARTICLE	IF	CITATIONS
781	Making the final cut: pathogenic amyloid- $\beta^2$ peptide generation by $\beta^3$ -secretase. <i>Cell Stress</i> , 2018, 2, 292-310.	1.4	100
782	Genetics of Alzheimer's Disease. <i>Dementia and Neurocognitive Disorders</i> , 2018, 17, 131.	0.4	50
783	The genes associated with early-onset Alzheimer's disease. <i>Oncotarget</i> , 2018, 9, 15132-15143.	0.8	78
784	Design of an Intelligent Cognition Assistant for People with Cognitive Impairment. , 2018, , .		4
785	Amyloid Beta Hypothesis: Attention to $\beta^2$ - and $\beta^3$ -Secretase Modulators. , 2018, , .		0
786	The Correlation between Genotype and Phenotype of Alzheimer's Disease. , 2018, 08, .		0
787	Decreased plasma C-reactive protein levels in <i>APOE</i> $\epsilon^4$ allele carriers. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1229-1240.	1.7	18
788	Linkage analysis of multiplex Caribbean Hispanic families loaded for unexplained early-onset cases identifies novel Alzheimer's disease loci. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 554-562.	1.2	8
789	Presenilin-mediated cleavage of APP regulates synaptotagmin-7 and presynaptic plasticity. <i>Nature Communications</i> , 2018, 9, 4780.	5.8	44
790	A Brief Synopsis on the Genetics of Alzheimer's Disease. <i>Current Genetic Medicine Reports</i> , 2018, 6, 133-135.	1.9	19
791	RAB10: an Alzheimer's disease resilience locus and potential drug target. <i>Clinical Interventions in Aging</i> , 2019, Volume 14, 73-79.	1.3	37
792	Opposite Epigenetic Associations With Alcohol Use and Exercise Intervention. <i>Frontiers in Psychiatry</i> , 2018, 9, 594.	1.3	15
793	Molecular Mechanisms of Synaptotoxicity and Neuroinflammation in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 963.	1.4	65
794	Altered $\beta^3$ -Secretase Processing of APP Disrupts Lysosome and Autophagosome Function in Monogenic Alzheimer's Disease. <i>Cell Reports</i> , 2018, 25, 3647-3660.e2.	2.9	95
795	Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 703-713.	1.8	63
796	Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFH1A) in SÄzary syndrome. <i>Cell Death and Disease</i> , 2018, 9, 1178.	2.7	10
797	SAR228810: an antibody for protofibrillar amyloid $\beta^2$ peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 117.	3.0	14
798	Preclinical Identification and Development of AM-6138: An Inhibitor of BACE1 for the Treatment of Alzheimer's Disease. <i>ACS Symposium Series</i> , 2018, , 29-52.	0.5	1

#	ARTICLE	IF	CITATIONS
799	Discovery and Chemical Development of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease. ACS Symposium Series, 2018, , 53-89.	0.5	0
800	A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect $\beta$ -secretase inhibitors. European Journal of Medicinal Chemistry, 2018, 159, 104-125.	2.6	16
801	The antimicrobial protection hypothesis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1602-1614.	0.4	305
802	Hydrophobic Modification of Carboxyl-Terminated Polyamidoamine Dendrimer Surface Creates a Potent Inhibitor of Amyloid- $\beta$ Fibrillation. Langmuir, 2018, 34, 14419-14427.	1.6	14
803	Past and Future of Drug Treatments for Alzheimer's Disease. Journal of Korean Neuropsychiatric Association, 2018, 57, 30.	0.2	6
804	The Early Events That Initiate $\beta$ -Amyloid Aggregation in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 359.	1.7	85
805	Questions concerning the role of amyloid- $\beta$ in the definition, aetiology and diagnosis of Alzheimer's disease. Acta Neuropathologica, 2018, 136, 663-689.	3.9	151
806	Determination of Parameters of Oxidative Stress in vitro Models of Neurodegenerative Diseases-A Review. Current Clinical Pharmacology, 2018, 13, 100-109.	0.2	19
807	Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases. International Journal of Molecular Sciences, 2018, 19, 3081.	1.8	28
808	Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review. Current Genomics, 2018, 19, 522-602.	0.7	65
809	Rho Guanine Nucleotide Exchange Factor <i>ARHGEF17</i> Is a Risk Gene for Intracranial Aneurysms. Circulation Genomic and Precision Medicine, 2018, 11, e002099.	1.6	18
810	The <i>BACE1</i> inhibitor <i>CNP</i> 520 for prevention trials in Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	112
811	Rare genetic variation in mitochondrial pathways influences the risk for Parkinson's disease. Movement Disorders, 2018, 33, 1591-1600.	2.2	51
812	A standard model of Alzheimer's disease?. Prion, 2018, 12, 261-265.	0.9	20
813	Non-Ashkenazi Jewish Origin is Associated with Early Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 877-884.	1.2	1
814	Passive $\beta$ Immunotherapy: Current Achievements and Future Perspectives. Molecules, 2018, 23, 1068.	1.7	41
815	Monogenic inheritance in early-onset dementia: illustration in Alzheimer's disease and frontotemporal lobar dementia. Psychologie & Neuropsychiatrie Du Vieillessement, 2018, 16, 289-297.	0.2	6
817	The Role of Gene Editing in Neurodegenerative Diseases. Cell Transplantation, 2018, 27, 364-378.	1.2	11

#	ARTICLE	IF	CITATIONS
818	Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine $\beta$ -Secretase (BACE1) Inhibitors via Active Conformation Stabilization. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5525-5546.	2.9	28
819	Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1530-1551.	1.7	70
820	AP180 N-Terminal Homology (ANTH) and Epsin N-Terminal Homology (ENTH) Domains: Physiological Functions and Involvement in Disease. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1111, 55-76.	0.8	6
821	Generation of a human induced pluripotent stem cell line from a patient with a rare A673T variant in amyloid precursor protein gene that reduces the risk for Alzheimer's disease. <i>Stem Cell Research</i> , 2018, 30, 96-99.	0.3	9
822	Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function. <i>Biological Psychiatry</i> , 2018, 84, 478-487.	0.7	41
823	Amyloid- $\beta$ /Drug Interactions from Computer Simulations and Cell-Based Assays. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S659-S672.	1.2	5
824	A New Fluorogenic Small-Molecule Labeling Tool for Surface Diffusion Analysis and Advanced Fluorescence Imaging of $\beta$ -Site Amyloid Precursor Protein-Cleaving Enzyme 1 Based on Silicone Rhodamine: SiR-BACE1. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6121-6139.	2.9	29
825	Relevance of N-terminal residues for amyloid- $\beta$ binding to platelet integrin $\alpha$ IIb $\beta$ 3, integrin outside-in signaling and amyloid- $\beta$ fibril formation. <i>Cellular Signalling</i> , 2018, 50, 121-130.	1.7	17
826	Functional analysis of juxta- and intra-membrane domains of murine APP by genome editing in Neuro2a cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 501, 1023-1028.	1.0	3
828	Oxidant/Antioxidant Imbalance in Alzheimer's Disease: Therapeutic and Diagnostic Prospects. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-16.	1.9	163
829	Neuronal Cell Death. <i>Physiological Reviews</i> , 2018, 98, 813-880.	13.1	737
830	Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects. <i>Journal of Genetics</i> , 2018, 97, 625-648.	0.4	7
831	Allosteric sodium binding cavity in GPR3: a novel player in modulation of $A\beta$ production. <i>Scientific Reports</i> , 2018, 8, 11102.	1.6	13
832	The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A Narrative Review. <i>Frontiers in Medicine</i> , 2018, 5, 108.	1.2	61
833	Use of Peptides for the Management of Alzheimer's Disease: Diagnosis and Inhibition. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 21.	1.7	79
834	Use of Eflornithine (DFMO) in the Treatment of Early Alzheimer's Disease: A Compassionate Use, Single-Case Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 60.	1.7	14
835	U1 snRNP Alteration and Neuronal Cell Cycle Reentry in Alzheimer Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 75.	1.7	16
836	Analyzing the Behavior of Neuronal Pathways in Alzheimer's Disease Using Petri Net Modeling Approach. <i>Frontiers in Neuroinformatics</i> , 2018, 12, 26.	1.3	12

#	ARTICLE	IF	CITATIONS
837	Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 336.	1.8	51
838	Cellular Receptors of Amyloid $\beta$ Oligomers ( $A\beta$ O) in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1884.	1.8	66
839	BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains. <i>PLoS ONE</i> , 2018, 13, e0200344.	1.1	13
840	Identification of missing variants by combining multiple analytic pipelines. <i>BMC Bioinformatics</i> , 2018, 19, 139.	1.2	10
841	Rational Design of Novel 1,3-Oxazine Based $\beta$ -Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust $A\beta$ Reduction in the Brain. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5122-5137.	2.9	29
842	Side-chain moieties from the N-terminal region of $A\beta$ are involved in an oligomer-stabilizing network of interactions. <i>PLoS ONE</i> , 2018, 13, e0201761.	1.1	14
843	Melatonin receptor type 1A gene linked to Alzheimer's disease in old age. <i>Sleep</i> , 2018, 41, .	0.6	30
844	Are N- and C-terminally truncated $A\beta$ species key pathological triggers in Alzheimer's disease?. <i>Journal of Biological Chemistry</i> , 2018, 293, 15419-15428.	1.6	84
845	Dysregulation of Neuronal Iron Homeostasis as an Alternative Unifying Effect of Mutations Causing Familial Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 533.	1.4	41
847	The Amyloid- $\beta$ Oligomer Hypothesis: Beginning of the Third Decade. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S567-S610.	1.2	572
848	Cu and Zn coordination to amyloid peptides: From fascinating chemistry to debated pathological relevance. <i>Coordination Chemistry Reviews</i> , 2018, 371, 38-55.	9.5	120
849	Prophylactic and Therapeutic Applications of Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer's Disease. , 2018, , 139-161.		1
850	What Sets Iceland Apart in Understanding Human Aging. , 2018, , 139-145.		0
851	Prion-like mechanisms in Alzheimer disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 153, 303-319.	1.0	42
852	Therapeutic strategies for targeting neurodegenerative protein misfolding disorders. <i>Current Opinion in Chemical Biology</i> , 2018, 44, 66-74.	2.8	23
853	Alzheimer's disease in the omics era. <i>Clinical Biochemistry</i> , 2018, 59, 9-16.	0.8	76
854	Drug development for Alzheimer's disease: review. <i>Journal of Drug Targeting</i> , 2019, 27, 164-173.	2.1	60
855	A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP $\beta$ -CTFs, Not $A\beta$ . <i>Neuron</i> , 2019, 104, 256-270.e5.	3.8	185

#	ARTICLE	IF	CITATIONS
856	Causative Mutations and Genetic Risk Factors in Sporadic Early Onset Alzheimer's Disease Before 51 Years. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 227-243.	1.2	39
857	Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 168, 99-145.	0.9	23
858	Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric A $\beta$ and Tau Species. <i>Frontiers in Neuroscience</i> , 2019, 13, 659.	1.4	198
859	Longitudinal PET Monitoring of Amyloidosis and Microglial Activation in a Second-Generation Amyloid- $\beta$ Mouse Model. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1787-1793.	2.8	41
860	Genes, pathways and risk prediction in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2019, 28, R235-R240.	1.4	16
862	His6, His13, and His14 residues in A $\beta$ 1-40 peptide significantly and specifically affect oligomeric equilibria. <i>Scientific Reports</i> , 2019, 9, 9449.	1.6	10
863	Novel amyloid precursor protein mutation, Val669Leu (Seoul APP), in a Korean patient with early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 84, 236.e1-236.e7.	1.5	10
864	Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer's Disease. <i>Planta Medica</i> , 2019, 85, 1316-1325.	0.7	25
865	The Amyloid Precursor Protein C-Terminal Domain Alters CA1 Neuron Firing, Modifying Hippocampus Oscillations and Impairing Spatial Memory Encoding. <i>Cell Reports</i> , 2019, 29, 317-331.e5.	2.9	24
867	Investigational BACE inhibitors for the treatment of Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 967-975.	1.9	94
868	Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2019, 39, 9645-9659.	1.7	22
869	Mixed Carboxyl and Hydrophobic Dendrimer Surface Inhibits Amyloid- $\beta$ Fibrillation: New Insight from the Generation Number Effect. <i>Langmuir</i> , 2019, 35, 14681-14687.	1.6	14
870	Performance evaluation of molecular docking and free energy calculations protocols using the D3R Grand Challenge 4 dataset. <i>Journal of Computer-Aided Molecular Design</i> , 2019, 33, 1031-1043.	1.3	12
871	Trifluoromethyl Dihydrothiazine-Based $\beta$ -Secretase (BACE1) Inhibitors with Robust Central $\beta$ -Amyloid Reduction and Minimal Covalent Binding Burden. <i>ChemMedChem</i> , 2019, 14, 1894-1910.	1.6	8
872	Trends of Protein Aggregation in Neurodegenerative Diseases. , 2019, , .		7
873	Facilitation of glutamate, but not GABA, release in Familial Alzheimer's APP mutant Knockin rats with increased $\beta$ -cleavage of APP. <i>Aging Cell</i> , 2019, 18, e13033.	3.0	33
874	History and progress of hypotheses and clinical trials for Alzheimer's disease. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 29.	7.1	370
875	IMPLICATIONS FOR BACE1 INHIBITOR CLINICAL TRIALS: ADULT CONDITIONAL BACE1 KNOCKOUT MICE EXHIBIT AXONAL ORGANIZATION DEFECTS IN THE HIPPOCAMPUS. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2019, 6, 1-7.	1.5	19



#	ARTICLE	IF	CITATIONS
876	Modeling of Alzheimer's Disease and Outlooks for its Therapy Using Induced Pluripotent Stem Cells. <i>Neurochemical Journal</i> , 2019, 13, 215-228.	0.2	0
877	Paul Greengard, Ph.D. (1925-2019). <i>Alzheimer's and Dementia</i> , 2019, 15, 1229-1235.	0.4	1
878	Molecular Mechanism of Binding Selectivity of Inhibitors toward BACE1 and BACE2 Revealed by Multiple Short Molecular Dynamics Simulations and Free-Energy Predictions. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4303-4318.	1.7	68
879	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. <i>Cell</i> , 2019, 179, 312-339.	13.5	1,675
880	Discovery of an Extremely Potent Thiazine-Based $\beta$ -Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9331-9337.	2.9	7
881	Expression Profiles of Long Noncoding RNAs in Intranasal LPS-Mediated Alzheimer's Disease Model in Mice. <i>BioMed Research International</i> , 2019, 2019, 1-14.	0.9	26
882	Genetic Analyses of Alzheimer's Disease in China: Achievements and Perspectives. <i>ACS Chemical Neuroscience</i> , 2019, 10, 890-901.	1.7	26
883	Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy. <i>British Journal of Pharmacology</i> , 2019, 176, 3447-3463.	2.7	115
884	Protective Variants in Alzheimer's Disease. <i>Current Genetic Medicine Reports</i> , 2019, 7, 1-12.	1.9	12
885	A short perspective on the long road to effective treatments for Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2019, 176, 3636-3648.	2.7	17
886	The $\beta$ -Secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid reduction to downstream disease-relevant effects. <i>British Journal of Pharmacology</i> , 2019, 176, 3435-3446.	2.7	17
887	Processing of Mutant $\beta$ -Amyloid Precursor Protein and the Clinicopathological Features of Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 10, 383.		27
888	Safety, Tolerability, and Pharmacokinetics of the $\beta$ -Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects. <i>Clinical and Translational Science</i> , 2019, 12, 545-555.	1.5	14
890	An App knock-in mouse inducing the formation of a toxic conformer of $\beta$ as a model for evaluating only oligomer-induced cognitive decline in Alzheimer's disease. <i>Biochemical and Biophysical Research Communications</i> , 2019, 515, 462-467.	1.0	14
891	NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer's models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 12516-12523.	3.3	132
892	$\beta$ 34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. <i>Nature Communications</i> , 2019, 10, 2240.	5.8	39
894	COMBINATION THERAPY FOR ALZHEIMER'S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2019, 6, 1-5.	1.5	29
895	New molecular approaches to Alzheimer's disease. <i>Clinical Biochemistry</i> , 2019, 72, 81-86.	0.8	18

#	ARTICLE	IF	CITATIONS
896	Non-conventional compounds with potential therapeutic effects against Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 375-395.	1.4	12
897	The Y682ENPTY687 motif of APP: Progress and insights toward a targeted therapy for Alzheimer's disease patients. <i>Ageing Research Reviews</i> , 2019, 52, 120-128.	5.0	19
898	Pharmacologic normalization of pathogenic dosage underlying genetic diseases: an overview of the literature and path forward. <i>Emerging Topics in Life Sciences</i> , 2019, 3, 53-62.	1.1	1
899	BACE-1 and $\beta$ -Secretase as Therapeutic Targets for Alzheimer's Disease. <i>Pharmaceuticals</i> , 2019, 12, 41.	1.7	78
900	A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment. <i>CNS Drugs</i> , 2019, 33, 251-263.	2.7	115
901	Integrated Analysis of Whole Exome Sequencing and Copy Number Evaluation in Parkinson's Disease. <i>Scientific Reports</i> , 2019, 9, 3344.	1.6	31
902	Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenues. <i>British Journal of Pharmacology</i> , 2019, 176, 3649-3665.	2.7	22
903	SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data. <i>Acta Neuropathologica</i> , 2019, 138, 173-186.	3.9	77
904	Detecting Diagnostic Biomarkers of Alzheimer's Disease by Integrating Gene Expression Data in Six Brain Regions. <i>Frontiers in Genetics</i> , 2019, 10, 157.	1.1	21
905	Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 845-847.	1.3	4
906	Development of Gleevec Analogues for Reducing Production of $\beta$ -Amyloid Peptides through Shifting $\beta$ -Cleavage of Amyloid Precursor Proteins. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3122-3134.	2.9	4
907	Charged aerosol detector HPLC as a characterization and quantification application of biopharmaceutically relevant polysialic acid from E. coli K1. <i>Journal of Chromatography A</i> , 2019, 1599, 85-94.	1.8	10
908	Lowering of Amyloid-Beta by $\beta$ -Secretase Inhibitors – Some Informative Failures. <i>New England Journal of Medicine</i> , 2019, 380, 1476-1478.	13.9	56
909	The Crocus sativus Compounds trans-Crocetin 4 and trans-Crocetin Modulate the Amyloidogenic Pathway and Tau Misprocessing in Alzheimer Disease Neuronal Cell Culture Models. <i>Frontiers in Neuroscience</i> , 2019, 13, 249.	1.4	42
910	PTCD1 Is Required for Mitochondrial Oxidative-Phosphorylation: Possible Genetic Association with Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2019, 39, 4636-4656.	1.7	26
911	Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1118, 83-116.	0.8	34
912	Benefits and Challenges of Rare Genetic Variation in Alzheimer's Disease. <i>Current Genetic Medicine Reports</i> , 2019, 7, 53-62.	1.9	9
913	$\beta$ -Secretase and its modulators: Twenty years and beyond. <i>Neuroscience Letters</i> , 2019, 701, 162-169.	1.0	46

#	ARTICLE	IF	CITATIONS
914	Fact, Fiction, or Evolution: Mechanism Hypothesis of Alzheimer's Disease. , 2019, , .		0
915	Neuropathology-driven Whole-genome Sequencing Study Points to Novel Candidate Genes for Healthy Brain Aging. Alzheimer Disease and Associated Disorders, 2019, 33, 7-14.	0.6	1
916	Alzheimer's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 231-255.	1.0	415
917	BACE1 partial deletion induces synaptic plasticity deficit in adult mice. Scientific Reports, 2019, 9, 19877.	1.6	25
918	Dreaming of a New World Where Alzheimer's Is a Treatable Disorder. Frontiers in Aging Neuroscience, 2019, 11, 317.	1.7	14
919	Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. CNS Drugs, 2019, 33, 99-106.	2.7	33
920	A critical appraisal of amyloid- $\beta$ -targeting therapies for Alzheimer's disease. Nature Reviews Neurology, 2019, 15, 73-88.	4.9	666
921	New evolutions in the BACE1 inhibitor field from 2014 to 2018. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 761-777.	1.0	57
922	Heteromultivalent peptide recognition by co-assembly of cyclodextrin and calixarene amphiphiles enables inhibition of amyloid fibrillation. Nature Chemistry, 2019, 11, 86-93.	6.6	148
923	Amyloid- $\beta$ immunotherapy for Alzheimer disease: Is it now a long shot?. Annals of Neurology, 2019, 85, 303-315.	2.8	126
924	A rare missense variant of <i>CASP7</i> is associated with familial late-onset Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 441-452.	0.4	39
925	Blood-Brain Barrier: From Physiology to Disease and Back. Physiological Reviews, 2019, 99, 21-78.	13.1	1,232
926	Significantly different contact patterns between A $\beta$ <sup>240</sup> and A $\beta$ <sup>242</sup> monomers involving the N-terminal region. Chemical Biology and Drug Design, 2019, 94, 1615-1625.	1.5	2
927	Interactions in DNA Condensation: An Important Factor for Improving the Efficacy of Gene Transfection. Bioconjugate Chemistry, 2019, 30, 284-292.	1.8	32
928	Alzheimer's Disease and Dementia. , 2019, , 25-82.		2
929	Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimer's and Dementia, 2019, 15, 245-257.	0.4	68
930	Specific mutations in presenilin 1 cause conformational changes in $\beta$ -secretase to modulate amyloid $\beta$ trimming. Journal of Biochemistry, 2019, 165, 37-46.	0.9	11
931	Inhibition of sphingomyelin synthase 1 ameliorates Alzheimer-like pathology in APP/PS1 transgenic mice through promoting lysosomal degradation of BACE1. Experimental Neurology, 2019, 311, 67-79.	2.0	13

#	ARTICLE	IF	CITATIONS
932	PET imaging of tau protein targets: a methodology perspective. <i>Brain Imaging and Behavior</i> , 2019, 13, 333-344.	1.1	43
933	Dysfunctional $\beta$ -Secretase in Familial Alzheimer's Disease. <i>Neurochemical Research</i> , 2019, 44, 5-11.	1.6	26
934	Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation. <i>Molecular Psychiatry</i> , 2020, 25, 1859-1875.	4.1	191
935	Discovery of AM-6494: A Potent and Orally Efficacious $\beta$ -Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2263-2281.	2.9	25
936	Apolipoprotein E impairs amyloid- $\beta$ fibril elongation and maturation. <i>FEBS Journal</i> , 2020, 287, 1208-1219.	2.2	11
937	Early Intervention in Alzheimer's Disease: How Early is Early Enough?. <i>Neuroscience Bulletin</i> , 2020, 36, 195-197.	1.5	29
938	The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. <i>Alzheimer's and Dementia</i> , 2020, 16, 1553-1560.	0.4	165
939	The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer's disease. <i>Immunology and Cell Biology</i> , 2020, 98, 28-41.	1.0	231
940	Mercury and Alzheimer's Disease: Hg(II) Ions Display Specific Binding to the Amyloid- $\beta$ Peptide and Hinder Its Fibrillization. <i>Biomolecules</i> , 2020, 10, 44.	1.8	26
941	Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 1.	7.1	1,354
942	Genetics of Alzheimer's disease: where we are, and where we are going. <i>Current Opinion in Neurobiology</i> , 2020, 61, 40-48.	2.0	144
943	Synthesis of a carbon-11 radiolabeled BACE1 inhibitor. <i>Medicinal Chemistry Research</i> , 2020, 29, 262-267.	1.1	0
944	Enhanced amyloid- $\beta$ generation by $\beta$ -secretase complex in DRM microdomains with reduced cholesterol levels. <i>Human Molecular Genetics</i> , 2020, 29, 382-393.	1.4	5
945	Interactions between Curcumin Derivatives and Amyloid- $\beta$ Fibrils: Insights from Molecular Dynamics Simulations. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 289-305.	2.5	44
946	A transcriptomic analysis of Nsmce1 overexpression in mouse hippocampal neuronal cell by RNA sequencing. <i>Functional and Integrative Genomics</i> , 2020, 20, 459-470.	1.4	5
947	4-Substituted 2-amino-3,4-dihydroquinazolines with a 3-hairpin turn side chain as novel inhibitors of BACE-1. <i>Bioorganic Chemistry</i> , 2020, 95, 103135.	2.0	7
948	Involvement of the nitric oxide signaling in modulation of naringin against intranasal manganese and intracerebroventricular $\beta$ -amyloid induced neurotoxicity in rats. <i>Journal of Nutritional Biochemistry</i> , 2020, 76, 108255.	1.9	22
949	Generation of a human induced pluripotent stem cell line (UEFi003-A) carrying heterozygous A673T variant in amyloid precursor protein associated with a reduced risk of Alzheimer's disease. <i>Stem Cell Research</i> , 2020, 48, 101968.	0.3	5

#	ARTICLE	IF	CITATIONS
950	The search for Alzheimer disease therapeutics â€” same targets, better trials?. <i>Nature Reviews Neurology</i> , 2020, 16, 597-598.	4.9	11
951	Modeling the Î²-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimerâ€™s disease. <i>Molecular Neurodegeneration</i> , 2020, 15, 60.	4.4	37
952	Discontinued disease-modifying therapies for Alzheimerâ€™s disease: status and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 919-933.	1.9	22
953	Molecular and cellular mechanisms underlying the pathogenesis of Alzheimerâ€™s disease. <i>Molecular Neurodegeneration</i> , 2020, 15, 40.	4.4	438
954	Blood cell-produced amyloid-Î² induces cerebral Alzheimer-type pathologies and behavioral deficits. <i>Molecular Psychiatry</i> , 2021, 26, 5568-5577.	4.1	32
955	From beta amyloid to altered proteostasis in Alzheimerâ€™s disease. <i>Ageing Research Reviews</i> , 2020, 64, 101126.	5.0	31
956	Passive immunotherapies targeting AÎ² and tau in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 144, 105010.	2.1	81
957	Diagnostic and therapeutic biomarkers for Alzheimerâ€™s disease in human-derived platelets. <i>Genes and Genomics</i> , 2020, 42, 1467-1475.	0.5	4
958	Presynaptic Vesicle Protein SEPTIN5 Regulates the Degradation of APP C-Terminal Fragments and the Levels of AÎ². <i>Cells</i> , 2020, 9, 2482.	1.8	8
959	The Role of APP O-Glycosylation in Alzheimerâ€™s Disease. <i>Biomolecules</i> , 2020, 10, 1569.	1.8	23
960	Looking Beyond the Core: The Role of Flanking Regions in the Aggregation of Amyloidogenic Peptides and Proteins. <i>Frontiers in Neuroscience</i> , 2020, 14, 611285.	1.4	52
961	Late-onset vs nonmendelian early-onset Alzheimer disease. <i>Neurology: Genetics</i> , 2020, 6, e512.	0.9	82
962	Genetics of Chronic Traumatic Encephalopathy. <i>Seminars in Neurology</i> , 2020, 40, 420-429.	0.5	8
963	It's complicated: The relationship between sleep and Alzheimer's disease in humans. <i>Neurobiology of Disease</i> , 2020, 144, 105031.	2.1	61
964	Nanoscale rearrangement of APP organization as a therapeutic target for Alzheimerâ€™s disease. <i>Medical Hypotheses</i> , 2020, 143, 110143.	0.8	4
965	Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimerâ€™s disease or should they be looking elsewhere?. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1241-1251.	2.5	15
966	<sc>AP</sc> reduces amyloidogenesis by promoting <sc>BACE</sc> 1 trafficking and degradation in neurons. <i>EMBO Reports</i> , 2020, 21, e47954.	2.0	36
967	Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use. <i>Medicinal Research Reviews</i> , 2021, 41, 2775-2803.	5.0	39

#	ARTICLE	IF	CITATIONS
968	Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1. <i>Molecular Neurodegeneration</i> , 2020, 15, 53.	4.4	44
969	Anatomical Landmarks and DAG Network Learning for Alzheimer's Disease Diagnosis. <i>IEEE Access</i> , 2020, 8, 206063-206073.	2.6	11
970	Recent Progress in Small Spirocyclic, Xanthene-Based Fluorescent Probes. <i>Molecules</i> , 2020, 25, 5964.	1.7	26
971	Alzheimer's genetic risk factor FERMT2 (Kindlin-2) controls axonal growth and synaptic plasticity in an APP-dependent manner. <i>Molecular Psychiatry</i> , 2021, 26, 5592-5607.	4.1	28
972	Mechanisms of neurodegeneration – Insights from familial Alzheimer's disease. <i>Seminars in Cell and Developmental Biology</i> , 2020, 105, 75-85.	2.3	35
973	Intracellular Trafficking Mechanisms of Synaptic Dysfunction in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 72.	1.8	31
974	Peripheral clearance of brain-derived A $\beta$ in Alzheimer's disease: pathophysiology and therapeutic perspectives. <i>Translational Neurodegeneration</i> , 2020, 9, 16.	3.6	83
975	Expanding the Phenotype of Frontotemporal Lobar Degeneration With FUS-Positive Pathology (FTLD-FUS). <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 809-812.	0.9	5
976	Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 58.	3.0	56
977	Partial reduction of amyloid $\beta$ production by $\beta$ -secretase inhibitors does not decrease synaptic transmission. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 63.	3.0	21
978	Effects of Disulfide Bonds on Binding of Inhibitors to $\beta$ -Amyloid Cleaving Enzyme 1 Decoded by Multiple Replica Accelerated Molecular Dynamics Simulations. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1811-1826.	1.7	42
979	Shifting paradigms: The central role of microglia in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 143, 104962.	2.1	60
980	Genetic architecture of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 143, 104976.	2.1	73
981	Synonymous variants associated with Alzheimer disease in multiplex families. <i>Neurology: Genetics</i> , 2020, 6, e450.	0.9	9
982	Tipping the Scales: Peptide-Dependent Dysregulation of Neural Circuit Dynamics in Alzheimer's Disease. <i>Neuron</i> , 2020, 107, 417-435.	3.8	90
983	Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials. <i>CNS Drugs</i> , 2020, 34, 785-794.	2.7	11
984	Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. <i>Acta Neuropathologica</i> , 2020, 139, 1001-1024.	3.9	46
985	Effect of Alzheimer's Disease Causative and Protective Mutations on the Hydration Environment of Amyloid- $\beta$ . <i>Journal of Physical Chemistry B</i> , 2020, 124, 2311-2322.	1.2	5

#	ARTICLE	IF	CITATIONS
986	NRBP1-Containing CRL2/CRL4A Regulates Amyloid $\beta^2$ Production by Targeting BRI2 and BRI3 for Degradation. <i>Cell Reports</i> , 2020, 30, 3478-3491.e6.	2.9	20
987	Real-time nanoscale organization of amyloid precursor protein. <i>Nanoscale</i> , 2020, 12, 8200-8215.	2.8	19
988	Molecular Pathogenesis and Interventional Strategies for Alzheimer's Disease: Promises and Pitfalls. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 472-488.	2.5	21
989	Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier "phenotypic variability in autosomal dominant Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 31.	2.4	14
990	Pathogenic PSEN1 Glu184Gly Mutation in a Family from Thailand with Probable Autosomal Dominant Early Onset Alzheimer's Disease. <i>Diagnostics</i> , 2020, 10, 135.	1.3	3
991	Protective effects of grape seed procyanidin on isoflurane-induced cognitive impairment in mice. <i>Pharmaceutical Biology</i> , 2020, 58, 200-207.	1.3	11
992	Current clinical approaches in neurodegenerative diseases. , 2020, , 79-124.		1
993	Good Cop, Bad Cop: Defining the Roles of $\beta^140p53$ in Cancer and Aging. <i>Cancers</i> , 2020, 12, 1659.	1.7	22
994	New BACE1 Chimeric Peptide Inhibitors Selectively Prevent $A\beta^{2PP-\beta^2}$ Cleavage Decreasing Amyloid- $\beta^2$ Production and Accumulation in Alzheimer's Disease Models. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1317-1337.	1.2	6
995	Resting State fMRI and Improved Deep Learning Algorithm for Earlier Detection of Alzheimer's Disease. <i>IEEE Access</i> , 2020, 8, 115383-115392.	2.6	40
996	Enhancing and Complementary Mechanisms of Synergistic Action of Acori Tatarinowii Rhizoma and Codonopsis Radix for Alzheimer's Disease Based on Systems Pharmacology. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-26.	0.5	4
997	<i>APP</i> -Induced Patterned Neurodegeneration Is Exacerbated by <i>APOE4</i> in <i>Caenorhabditis elegans</i> . <i>G3: Genes, Genomes, Genetics</i> , 2020, 10, 2851-2861.	0.8	4
998	An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis. <i>Alzheimer's and Dementia</i> , 2020, 16, 1582-1590.	0.4	18
999	A Pooled Analysis of Three Randomized Phase I/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by Umibecestat. <i>Clinical and Translational Science</i> , 2020, 13, 1316-1326.	1.5	6
1000	Clinical and cellular aspects of traumatic brain injury. , 2020, , 745-765.		1
1001	Neuronal chloride transporters in neurodegenerative diseases. , 2020, , 641-684.		3
1002	Pathogenic $A\beta^2$ generation in familial Alzheimer's disease: novel mechanistic insights and therapeutic implications. <i>Current Opinion in Neurobiology</i> , 2020, 61, 73-81.	2.0	22
1003	The multiplex model of the genetics of Alzheimer's disease. <i>Nature Neuroscience</i> , 2020, 23, 311-322.	7.1	291

#	ARTICLE	IF	CITATIONS
1004	Genetic architecture of neurodegenerative dementias. <i>Neuropharmacology</i> , 2020, 168, 108014.	2.0	5
1006	Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 319.	1.4	15
1007	The interRAI Suite of Mental Health Assessment Instruments: An Integrated System for the Continuum of Care. <i>Frontiers in Psychiatry</i> , 2019, 10, 926.	1.3	70
1008	Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2020, 192, 112163.	2.6	85
1009	Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2. <i>Neurobiology of Disease</i> , 2020, 139, 104817.	2.1	26
1010	Elucidating the Effect of Static Electric Field on Amyloid Beta 1 $\beta$ 42 Supramolecular Assembly. <i>Journal of Molecular Graphics and Modelling</i> , 2020, 96, 107535.	1.3	14
1011	Augmentation of Bri2 molecular chaperone activity against amyloid- $\beta$ 2 reduces neurotoxicity in mouse hippocampus in vitro. <i>Communications Biology</i> , 2020, 3, 32.	2.0	42
1012	Galectin 3 $\beta$ binding protein suppresses amyloid- $\beta$ 2 production by modulating $\beta$ 2-cleavage of amyloid precursor protein. <i>Journal of Biological Chemistry</i> , 2020, 295, 3678-3691.	1.6	29
1013	Predicted loss and gain of function mutations in ACO1 are associated with erythropoiesis. <i>Communications Biology</i> , 2020, 3, 189.	2.0	30
1014	Amyloid $\beta$ 2-protein and beyond: the path forward in Alzheimer's disease. <i>Current Opinion in Neurobiology</i> , 2020, 61, 116-124.	2.0	87
1015	Interaction Volume Is a Measure of the Aggregation Propensity of Amyloid- $\beta$ 2. <i>Journal of Physical Chemistry Letters</i> , 2020, 11, 3993-4000.	2.1	5
1016	Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?. <i>Biochemical Pharmacology</i> , 2020, 177, 113945.	2.0	62
1017	New Insights into the Molecular Bases of Familial Alzheimer's Disease. <i>Journal of Personalized Medicine</i> , 2020, 10, 26.	1.1	19
1018	Substrate recruitment by $\beta$ 3-secretase. <i>Seminars in Cell and Developmental Biology</i> , 2020, 105, 54-63.	2.3	13
1019	Synaptic Vesicle Protein 2B Negatively Regulates the Amyloidogenic Processing of A $\beta$ 2PP as a Novel Interaction Partner of BACE1. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 173-185.	1.2	7
1020	Regulatory function of praja ring finger ubiquitin ligase 2 mediated by the $\beta$ 2/P2rx3/P2rx7 axis in mouse hippocampal neuronal cells. <i>American Journal of Physiology - Cell Physiology</i> , 2020, 318, C1123-C1135.	2.1	9
1021	Oligomerization and Conformational Change Turn Monomeric $\beta$ 2-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer's Pathogenesis. <i>Molecules</i> , 2020, 25, 1659.	1.7	60
1022	Neurodegenerative and Hepatorenal Disorders Induced Via Aluminum Chloride in Murine System: Impact of $\beta$ 2-Secretase, MAPK, and KIM. <i>Biological Trace Element Research</i> , 2021, 199, 227-236.	1.9	16



#	ARTICLE	IF	CITATIONS
1023	The $\beta$ -Secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 745-756.	0.7	336
1024	Functional effects of protein variants. <i>Biochimie</i> , 2021, 180, 104-120.	1.3	30
1025	The Ups and Downs of BACE1: Walking a Fine Line between Neurocognitive and Other Psychiatric Symptoms of Alzheimer's Disease. <i>Neuroscientist</i> , 2021, 27, 222-234.	2.6	4
1026	Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020). <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 25-52.	2.4	22
1027	Alzheimer's protection effect of A673T mutation may be driven by lower $A\beta$ oligomer binding affinity. <i>Journal of Neurochemistry</i> , 2021, 157, 1316-1330.	2.1	20
1028	Mechanisms of neuronal survival safeguarded by endocytosis and autophagy. <i>Journal of Neurochemistry</i> , 2021, 157, 263-296.	2.1	25
1029	Dissecting Alzheimer's disease pathogenesis in human 2D and 3D models. <i>Molecular and Cellular Neurosciences</i> , 2021, 110, 103568.	1.0	30
1030	$\beta$ -amyloid: The known unknowns. <i>Ageing Research Reviews</i> , 2021, 65, 101212.	5.0	27
1031	Genetic variants in glutamate-, $A\beta$ , and tau-related pathways determine polygenic risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 101, 299.e13-299.e21.	1.5	7
1032	Compact fibril-like structure of amyloid $\beta$ -peptide (1-42) monomers. <i>Chemical Communications</i> , 2021, 57, 947-950.	2.2	15
1033	Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives. <i>Science China Life Sciences</i> , 2021, 64, 926-937.	2.3	12
1034	Rational designs of in vivo CRISPR-Cas delivery systems. <i>Advanced Drug Delivery Reviews</i> , 2021, 168, 3-29.	6.6	125
1035	Hydration Thermodynamics of the N-Terminal FAD Mutants of Amyloid- $\beta$ . <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 298-310.	2.5	7
1036	Nanodelivery of oxiracetam enhances memory, functional recovery and induces neuroprotection following concussive head injury. <i>Progress in Brain Research</i> , 2021, 265, 139-230.	0.9	9
1037	Effects of Ions and Small Compounds on the Structure of $A\beta$ 42 Monomers. <i>Journal of Physical Chemistry B</i> , 2021, 125, 1085-1097.	1.2	3
1038	Post-Translational Modifications of BACE1 in Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2022, 20, 211-222.	1.4	7
1039	Insight into the genetic etiology of Alzheimer's disease: A comprehensive review of the role of rare variants. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12155.	1.2	33
1040	Is $\beta$ -secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?. <i>Journal of Biological Chemistry</i> , 2021, 296, 100489.	1.6	32

#	ARTICLE	IF	CITATIONS
1041	Rare Coding Variants Associated with Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 435-453.	0.8	0
1042	Genetic Aspects of Early-Onset Alzheimer's Disease. , 2021, , 29-39.		0
1043	Hydrophilic loop 1 of Presenilin-1 and the APP GxxxG transmembrane motif regulate $\beta$ -secretase function in generating Alzheimer-causing $A\beta$ peptides. <i>Journal of Biological Chemistry</i> , 2021, 296, 100393.	1.6	22
1044	Autophagy-Dependent Increased ADAM10 Mature Protein Induced by TFEB Overexpression Is Mediated Through PPAR $\alpha$ . <i>Molecular Neurobiology</i> , 2021, 58, 2269-2283.	1.9	5
1045	Genetics of Alzheimer's disease. <i>Wiener Medizinische Wochenschrift</i> , 2021, 171, 249-256.	0.5	11
1046	Metabolic disorder in Alzheimer's disease. <i>Metabolic Brain Disease</i> , 2021, 36, 781-813.	1.4	23
1047	Molecular Genetics of Early- and Late-Onset Alzheimer's Disease. <i>Current Gene Therapy</i> , 2021, 21, 43-52.	0.9	16
1048	Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia. <i>NeuroMolecular Medicine</i> , 2021, 23, 1-24.	1.8	9
1050	Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based $\beta$ -Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 1873-1888.	2.9	30
1051	A promising new $\beta$ -secretase modulator for Alzheimer's disease. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	1
1052	Apoptotic neurons and amyloid-beta clearance by phagocytosis in Alzheimer's disease: Pathological mechanisms and therapeutic outlooks. <i>European Journal of Pharmacology</i> , 2021, 895, 173873.	1.7	24
1053	Mechanistic insights into the pathogenesis of neurodegenerative diseases: towards the development of effective therapy. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 2739-2752.	1.4	12
1054	Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 293.	4.5	57
1055	Searching the Dark Genome for Alzheimer's Disease Risk Variants. <i>Brain Sciences</i> , 2021, 11, 332.	1.1	10
1056	Genetic testing in dementia: A medical genetics perspective. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1158-1170.	1.3	9
1057	Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective $\beta$ -Secretase (BACE1) Inhibitors over BACE2. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3075-3085.	2.9	11
1058	In silico Analysis of Polymorphisms in microRNAs Deregulated in Alzheimer Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 631852.	1.4	4
1060	The Effect of TCM-Induced HAMP on Key Enzymes in the Hydrolysis of AD Model Cells. <i>Neurochemical Research</i> , 2021, 46, 1068-1080.	1.6	2

#	ARTICLE	IF	CITATIONS
1061	Toxic Amyloid- $\beta$ 42 Conformer May Accelerate the Onset of Alzheimer's Disease in the Preclinical Stage. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 639-646.	1.2	2
1062	MicroRNA-340-5p increases telomere length by targeting telomere protein POT1 to improve Alzheimer's disease in mice. <i>Cell Biology International</i> , 2021, 45, 1306-1315.	1.4	9
1063	Impact of pre- and post-variant filtration strategies on imputation. <i>Scientific Reports</i> , 2021, 11, 6214.	1.6	3
1064	Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer's Disease. <i>Sensors</i> , 2021, 21, 2067.	2.1	19
1065	Accelerated long-term forgetting is a BACE1 inhibitor-reversible incipient cognitive phenotype in Alzheimer's disease model mice. <i>Neuropsychopharmacology Reports</i> , 2021, 41, 255-259.	1.1	5
1066	The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2021, 58, 4038-4050.	1.9	16
1067	Protective genes and pathways in Alzheimer's disease: moving towards precision interventions. <i>Molecular Neurodegeneration</i> , 2021, 16, 29.	4.4	58
1068	Emerging genetic complexity and rare genetic variants in neurodegenerative brain diseases. <i>Genome Medicine</i> , 2021, 13, 59.	3.6	16
1069	COVID-19 and Alzheimer's disease: how one crisis worsens the other. <i>Translational Neurodegeneration</i> , 2021, 10, 15.	3.6	74
1070	Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 321-336.	1.2	17
1071	Alzheimer's disease. <i>Lancet, The</i> , 2021, 397, 1577-1590.	6.3	1,530
1072	Structural Analysis of the Simultaneous Activation and Inhibition of $\beta$ -Secretase Activity in the Development of Drugs for Alzheimer's Disease. <i>Pharmaceutics</i> , 2021, 13, 514.	2.0	8
1073	Whole-genome sequencing reveals new Alzheimer's disease-associated rare variants in loci related to synaptic function and neuronal development. <i>Alzheimer's and Dementia</i> , 2021, 17, 1509-1527.	0.4	50
1074	How understudied populations have contributed to our understanding of Alzheimer's disease genetics. <i>Brain</i> , 2021, 144, 1067-1081.	3.7	10
1075	Alzheimer disease. <i>Nature Reviews Disease Primers</i> , 2021, 7, 33.	18.1	784
1076	Understanding amphisomes. <i>Biochemical Journal</i> , 2021, 478, 1959-1976.	1.7	57
1078	Donanemab in Early Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1691-1704.	13.9	633
1079	What Can Genome Editing Be Used for?. , 2021, , 141-191.		0

#	ARTICLE	IF	CITATIONS
1080	Structural Studies Providing Insights into Production and Conformational Behavior of Amyloid- $\beta^2$ Peptide Associated with Alzheimer's Disease Development. <i>Molecules</i> , 2021, 26, 2897.	1.7	15
1081	Calcium Dyshomeostasis in Alzheimer's Disease Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4914.	1.8	76
1082	MicroRNA-4422-5p as a Negative Regulator of Amyloidogenic Secretases: A Potential Biomarker for Alzheimer's Disease. <i>Neuroscience</i> , 2021, 463, 108-115.	1.1	6
1083	Peptides Derived from Growth Factors to Treat Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6071.	1.8	10
1084	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
1085	GPR40 receptor agonist TAK-875 improves cognitive deficits and reduces $\beta^2$ -amyloid production in APP <sup>swE</sup> /PS1 <sup>dE9</sup> mice. <i>Psychopharmacology</i> , 2021, 238, 2133-2146.	1.5	4
1086	Base editing strategy for insertion of the A673T mutation in the APP gene to prevent the development of AD in vitro. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 24, 253-263.	2.3	17
1087	Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8076-8100.	2.9	10
1088	Dietary intervention with edible medicinal plants and derived products for prevention of Alzheimer's disease: A compendium of time-tested strategy. <i>Journal of Functional Foods</i> , 2021, 81, 104463.	1.6	15
1090	Nutraceutical and Probiotic Approaches to Examine Molecular Interactions of the Amyloid Precursor Protein APP in <i>Drosophila</i> Models of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7022.	1.8	5
1091	Design, synthesis and in-vitro evaluation of fluorinated triazoles as multi-target directed ligands for Alzheimer disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 42, 127999.	1.0	6
1092	Sanweidoukou decoction, a Chinese herbal formula, ameliorates $\beta^2$ -amyloid protein-induced neuronal insult via modulating MAPK/NF- $\kappa$ B signaling pathways: Studies in vivo and in vitro. <i>Journal of Ethnopharmacology</i> , 2021, 273, 114002.	2.0	12
1093	GPR120 Signaling Controls Amyloid- $\beta^2$ Degrading Activity of Matrix Metalloproteinases. <i>Journal of Neuroscience</i> , 2021, 41, 6173-6185.	1.7	7
1094	Refining the amyloid $\beta^2$ peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. <i>Journal of Neurochemistry</i> , 2021, 159, 234-257.	2.1	8
1095	Neuronal spreading and plaque induction of intracellular A $\beta^2$ and its disruption of A $\beta^2$ homeostasis. <i>Acta Neuropathologica</i> , 2021, 142, 669-687.	3.9	17
1096	Genetic signature of human longevity in PKC and NF- $\kappa$ B signaling. <i>Aging Cell</i> , 2021, 20, e13362.	3.0	12
1097	The complexity of Alzheimer's disease: an evolving puzzle. <i>Physiological Reviews</i> , 2021, 101, 1047-1081.	13.1	110
1098	Gene therapy using A $\beta^2$ variants for amyloid reduction. <i>Molecular Therapy</i> , 2021, 29, 2294-2307.	3.7	7

#	ARTICLE	IF	CITATIONS
1099	Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (HSD17B14) with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2634-2651.	3.0	9
1100	Suppression of amyloid- $\beta$ secretion from neurons by <i>cis</i> -, <i>trans</i> - $\alpha$ -octadecadienoic acid, an isomer of conjugated linoleic acid. <i>Journal of Neurochemistry</i> , 2021, 159, 603-617.	2.1	3
1101	The <i>Uppsala APP</i> deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid $\beta$ fibril formation. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	23
1103	The Amyloid- $\beta$ Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021, 26, 5481-5503.	4.1	478
1104	Diagnosi clinicolaboratoristica della malattia di Alzheimer. <i>EMC - Neurologia</i> , 2021, 21, 1-15.	0.0	0
1105	Cross-Seeded Fibrillation Induced by Pyroglutamate-3 and Truncated A $\beta$ <sub>40</sub> Variants Leads to A $\beta$ <sub>40</sub> Structural Polymorphism Modulation and Elevated Toxicity. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3625-3637.	1.7	11
1106	Coassembly of Macrocyclic Amphiphiles for Anti- $\beta$ -Amyloid Therapy of Alzheimer's Disease. <i>CCS Chemistry</i> , 2021, 3, 2485-2497.	4.6	26
1107	JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14175-14191.	2.9	10
1108	<i>APOE3</i> -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. <i>Science Translational Medicine</i> , 2021, 13, eabc9375.	5.8	37
1109	Discovery of Extremely Selective Fused Pyridine-Derived $\beta$ -Site Amyloid Precursor Protein-Cleaving Enzyme (BACE1) Inhibitors with High In Vivo Efficacy through 10s Loop Interactions. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14165-14174.	2.9	4
1110	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. <i>Nature Reviews Neurology</i> , 2021, 17, 703-714.	4.9	65
1111	Lemur tail kinase 1 (LMTK1) regulates the endosomal localization of $\beta$ -secretase BACE1. <i>Journal of Biochemistry</i> , 2021, 170, 729-738.	0.9	4
1112	Improvement of cognitive performance by a nutraceutical formulation: Underlying mechanisms revealed by laboratory studies. <i>Free Radical Biology and Medicine</i> , 2021, 174, 281-304.	1.3	3
1113	Synthesis, biological evaluation and molecular modeling of benzofuran piperidine derivatives as A $\beta$ antiaggregant. <i>European Journal of Medicinal Chemistry</i> , 2021, 222, 113541.	2.6	12
1114	Evolution of genetic testing supports precision medicine for caring Alzheimer's disease patients. <i>Current Opinion in Pharmacology</i> , 2021, 60, 275-280.	1.7	5
1115	Structure Dependent Differential Modulation of A $\beta$ Fibrillization by Selenadiazole-Based Inhibitors. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3806-3817.	1.7	2
1116	Clinical trials for Alzheimer's disease in Down syndrome. , 2022, , 307-318.		0
1117	Genetics of Alzheimer's disease in adults with Down syndrome. , 2022, , 193-208.		0

#	ARTICLE	IF	CITATIONS
1118	The Ups and Downs of Amyloid in Alzheimer's. <i>Journal of Prevention of Alzheimer's Disease</i> , 2022, 9, 1-4.	1.5	2
1119	Enlargement of early endosomes and traffic jam in basal forebrain cholinergic neurons in Alzheimer's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 179, 207-218.	1.0	2
1120	Early-Onset Alzheimer's Disease: What Is Missing in Research?. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 4.	2.0	88
1121	Local Strategies of Strengthening the Caregiving Potential of Families of People with Alzheimer's Disease—Good Practices Introduced in Poland. , 2021, , 137-154.		0
1124	Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. <i>Alzheimer's and Dementia</i> , 2021, 17, 1365-1382.	0.4	43
1125	Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12114.	1.8	49
1126	Autosomal Dominant Alzheimer's Disease: Underlying Causes. , 2014, , 27-47.		2
1127	Dementia: Genes, Environments, Interactions. , 2014, , 201-231.		2
1128	The Genetic Architecture of Idiopathic Scoliosis. , 2015, , 71-89.		2
1130	Amyloid- $\beta$ and Tau at the Crossroads of Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1184, 187-203.	0.8	115
1131	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer's disease. , 2020, , 469-504.		5
1132	Application of yeast to studying amyloid and prion diseases. <i>Advances in Genetics</i> , 2020, 105, 293-380.	0.8	19
1134	Amyloidogenic processing of Alzheimer's disease $\beta$ -amyloid precursor protein induces cellular iron retention. <i>Molecular Psychiatry</i> , 2020, 25, 1958-1966.	4.1	52
1135	Insights into amyloid disease from fly models. <i>Essays in Biochemistry</i> , 2014, 56, 69-83.	2.1	1
1136	Amyloid $\beta$ -peptide and Alzheimer's disease. <i>Essays in Biochemistry</i> , 2014, 56, 99-110.	2.1	20
1137	On Short Cuts: The Complexity of Studying the Early Diagnosis and Prevention of Alzheimer's Disease. , 2016, , 41-61.		3
1147	BACE2, a conditional $\beta$ -secretase, contributes to Alzheimer's disease pathogenesis. <i>JCI Insight</i> , 2019, 4, .	2.3	59
1148	Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. <i>Journal of Clinical Investigation</i> , 2018, 128, 2144-2155.	3.9	105

#	ARTICLE	IF	CITATIONS
1149	Blood will out: vascular contributions to Alzheimer's disease. <i>Journal of Clinical Investigation</i> , 2018, 128, 556-563.	3.9	73
1150	Hypothesis-driven genomics pays off. <i>Genome Biology</i> , 2012, 13, 176.	13.9	2
1151	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 5.	2.4	27
1152	Can Anti- $\text{A}\beta$ -amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?. <i>Neurology: Genetics</i> , 2021, 7, e535.	0.9	10
1153	Rare Functional Variant in TM2D3 is Associated with Late-Onset Alzheimer's Disease. <i>PLoS Genetics</i> , 2016, 12, e1006327.	1.5	47
1154	Rare Variants in PLXNA4 and Parkinson's Disease. <i>PLoS ONE</i> , 2013, 8, e79145.	1.1	16
1155	Mechanistic Phenotypes: An Aggregative Phenotyping Strategy to Identify Disease Mechanisms Using GWAS Data. <i>PLoS ONE</i> , 2013, 8, e81503.	1.1	15
1156	Long-Term Oral Administration of Hop Flower Extracts Mitigates Alzheimer Phenotypes in Mice. <i>PLoS ONE</i> , 2014, 9, e87185.	1.1	21
1157	Evidence of a Novel Mechanism for Partial $\text{A}\beta$ -Secretase Inhibition Induced Paradoxical Increase in Secreted Amyloid $\text{A}\beta$ Protein. <i>PLoS ONE</i> , 2014, 9, e91531.	1.1	19
1158	Amyloid- $\text{A}\beta$ and Proinflammatory Cytokines Utilize a Prion Protein-Dependent Pathway to Activate NADPH Oxidase and Induce Cofilin-Actin Rods in Hippocampal Neurons. <i>PLoS ONE</i> , 2014, 9, e95995.	1.1	58
1159	Integrating EMR-Linked and In Vivo Functional Genetic Data to Identify New Genotype-Phenotype Associations. <i>PLoS ONE</i> , 2014, 9, e100322.	1.1	4
1160	Gene-Based Rare Allele Analysis Identified a Risk Gene of Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e107983.	1.1	11
1161	Examination of Candidate Exonic Variants for Association to Alzheimer Disease in the Amish. <i>PLoS ONE</i> , 2015, 10, e0118043.	1.1	13
1162	Perinatal Choline Supplementation Reduces Amyloidosis and Increases Choline Acetyltransferase Expression in the Hippocampus of the APPswePS1dE9 Alzheimer's Disease Model Mice. <i>PLoS ONE</i> , 2017, 12, e0170450.	1.1	34
1163	The protective mutation A673T in amyloid precursor protein gene decreases $\text{A}\beta$ peptides production for 14 forms of Familial Alzheimer's Disease in SH-SY5Y cells. <i>PLoS ONE</i> , 2020, 15, e0237122.	1.1	11
1164	Functional Amyloids and their Possible Influence on Alzheimer Disease. <i>Discoveries</i> , 2017, 5, e79.	1.5	9
1165	Alzheimer's disease: amyloid-based pathogenesis and potential therapies. <i>Cell Stress</i> , 2018, 2, 150-161.	1.4	27
1166	$\text{A}\beta$ Plaques. <i>Free Neuropathology</i> , 2020, 1, .	2.4	21

#	ARTICLE	IF	CITATIONS
1167	Reversal of cognitive decline: A novel therapeutic program. <i>Aging</i> , 2014, 6, 707-717.	1.4	160
1168	Deletion of the $\beta$ -secretase subunits <i>Aph1B/C</i> impairs memory and worsens the deficits of knock-in mice modeling the Alzheimer-like familial Danish dementia. <i>Oncotarget</i> , 2016, 7, 11923-11944.	0.8	17
1169	The Panomics Approach in Neurodegenerative Disorders. <i>Current Medicinal Chemistry</i> , 2019, 26, 1712-1720.	1.2	3
1170	Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by Molecular Tweezers; - from the Test Tube to Animal Models. <i>Current Pharmaceutical Design</i> , 2014, 20, 2469-2483.	0.9	40
1171	New Mechanism of Amyloid Fibril Formation. <i>Current Protein and Peptide Science</i> , 2019, 20, 630-640.	0.7	16
1172	The Normal and Pathologic Roles of the Alzheimer's $\gamma$ -secretase, BACE1. <i>Current Alzheimer Research</i> , 2014, 11, 441-449.	0.7	40
1173	Small Molecules and Alzheimer's Disease: Misfolding, Metabolism and Imaging. <i>Current Alzheimer Research</i> , 2015, 12, 445-461.	0.7	21
1174	Molecular Basis of Familial and Sporadic Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 952-963.	0.7	241
1175	Therapeutic Strategies Targeting Amyloid- $\beta$ in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2019, 16, 418-452.	0.7	88
1176	Insights into A $\beta$ Aggregation: A Molecular Dynamics Perspective. <i>Current Topics in Medicinal Chemistry</i> , 2013, 12, 2596-2610.	1.0	44
1177	The Links between Cardiovascular Diseases and Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2020, 19, 152-169.	1.4	23
1178	Oxidative Stress in the Pathogenesis of Alzheimer's Disease and Cerebrovascular Disease with Therapeutic Implications. <i>CNS and Neurological Disorders - Drug Targets</i> , 2020, 19, 94-108.	0.8	20
1179	Yeast contributions to Alzheimer's Disease. <i>Journal of Human and Clinical Genetics</i> , 2020, 2, 1-19.	0.2	8
1180	Neuropathological approaches to cerebral aging and neuroplasticity. <i>Dialogues in Clinical Neuroscience</i> , 2013, 15, 29-43.	1.8	57
1181	Neuroprotective Effects of Coffee Bioactive Compounds: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 107.	1.8	97
1182	Advance research on strategies for the prevention of Alzheimer's disease. <i>Shenzhen Daxue Xuebao (Ligong Ban)/Journal of Shenzhen University Science and Engineering</i> , 2013, 30, 331-348.	0.1	2
1183	Application of next-generation sequencing technologies in Neurology. <i>Annals of Translational Medicine</i> , 2014, 2, 125.	0.7	28
1184	Finding chemopreventatives to reduce amyloid beta in yeast. <i>Neural Regeneration Research</i> , 2016, 11, 244.	1.6	4



#	ARTICLE	IF	CITATIONS
1185	Mutations of beta-amyloid precursor protein alter the consequence of Alzheimer's disease pathogenesis. <i>Neural Regeneration Research</i> , 2019, 14, 658.	1.6	27
1186	Physiological effects of amyloid precursor protein and its derivatives on neural stem cell biology and signaling pathways involved. <i>Neural Regeneration Research</i> , 2019, 14, 1661.	1.6	22
1187	The Potential Role of Epigenetics in Alzheimer's Disease Etiology. <i>Biological Systems, Open Access</i> , 2012, 02, .	0.1	3
1188	Selective manipulation of aging: a novel strategy for the treatment of neurodegenerative disorders. <i>Swiss Medical Weekly</i> , 2014, 144, w13917.	0.8	11
1189	APP and APLP2 interact with the synaptic release machinery and facilitate transmitter release at hippocampal synapses. <i>ELife</i> , 2015, 4, e09743.	2.8	73
1190	Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer's disease. <i>ELife</i> , 2018, 7, .	2.8	62
1191	Opposite changes in APP processing and human A $\beta$ levels in rats carrying either a protective or a pathogenic APP mutation. <i>ELife</i> , 2020, 9, .	2.8	32
1192	Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimer's Disease Pathogenesis. <i>Molecular Biology</i> , 2021, 55, 670-682.	0.4	10
1193	A C-terminal ataxin-2 disordered region promotes Huntingtin protein aggregation and neurodegeneration in <i>Drosophila</i> models of Huntington's disease. <i>G3: Genes, Genomes, Genetics</i> , 2021, 11, .	0.8	3
1195	Amyloidogenic Processing of Amyloid Precursor Protein Drives Stretch-Induced Disruption of Axonal Transport in hiPSC-Derived Neurons. <i>Journal of Neuroscience</i> , 2021, 41, 10034-10053.	1.7	14
1196	Engineered pegRNAs improve prime editing efficiency. <i>Nature Biotechnology</i> , 2022, 40, 402-410.	9.4	293
1197	Letter Concerning Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease by Moghavem, Henderson, and Greicius. <i>Annals of Neurology</i> , 2021, 90, 1004-1006.	2.8	0
1199	Personalized Neurology. , 2013, , 575-612.		0
1201	The Role of Metals in Alzheimer's Disease. <i>2-Oxoglutarate-Dependent Oxygenases</i> , 2013, , 80-97.	0.8	3
1202	Challenges in the Neuropathological Diagnosis of Dementias. <i>International Journal of Neuropathology</i> , 0, , .	0.0	2
1205	Metal Exposure and Alzheimer's Pathophysiology. <i>Biochemistry &amp; Pharmacology: Open Access</i> , 2014, 03, .	0.2	0
1206	Genetic Risk Factors for Alzheimer's Disease. , 2014, , 49-64.		0
1207	Can Microbes Play a Role in the Pathogenesis of Alzheimer Disease?. , 2014, , 129-146.		0

#	ARTICLE	IF	CITATIONS
1209	Genetic Risk Factors for Neurodegenerative Diseases. , 2015, , 117-134.		0
1211	Frontiers in Clinical Drug Research - Alzheimer Disorders. , 2015, , .		0
1212	App. , 2016, , 1-8.		0
1213	Aspects of Autophagy in Inflammatory Bowel Disease. , 2016, , 235-265.		0
1216	Biomarkers in Mild Stages of Alzheimerâ€™s disease: Utility in clinical practice and their relation with nutritional and lifestyle factors. Functional Foods in Health and Disease, 2016, 6, 627.	0.3	0
1217	Verubecestat. , 2017, , 204-251.		0
1219	App. , 2017, , 1-8.		0
1223	App. , 2018, , 367-373.		0
1224	Alzheimer's Disease â†. , 2018, , .		0
1225	Solving the Puzzle of Neurodegeneration. , 2018, , 1-22.		2
1231	Statistical Methods and Software for Substance Use and Dependence Genetic Research. Current Genomics, 2019, 20, 172-183.	0.7	0
1233	Contributing Factors of Neurodegeneration in Alzheimerâ€™s Disease. , 0, , 69-84.		0
1234	Drug development against dementia based on understanding of molecular and cellular pathogenesis. Drug Delivery System, 2019, 34, 346-351.	0.0	0
1237	Genetics of dementia. , 2020, , 127-146.		0
1238	Alzheimerâ€™s Disease: Etiology, Neuropathology and Pathogenesis. , 0, , 1-22.		22
1239	Is It the Twilight of BACE1 Inhibitors?. Current Neuropharmacology, 2020, 19, 61-77.	1.4	15
1240	Genome-wide association study identifies quantitative trait loci affecting cattle temperament. Zoological Research, 2022, 43, 14-25.	0.9	8
1241	Targeting Alzheimerâ€™s disease and related dementias with CRISPR and human pluripotent stem cell technologies. , 2022, , 65-80.		0

#	ARTICLE	IF	CITATIONS
1242	Endoplasmic reticulum stress and associated ROS in disease pathophysiology applications. , 2020, , 265-297.		0
1243	Verhaltens- und Neurogenetik. , 2020, , 813-895.		0
1244	Prevention of Age-Related Cognitive Impairment, Alzheimer's Disease, and Dementia. , 2020, , 1-9.		0
1245	Alzheimer's disease and other dementias. , 2020, , C24.4.2-C24.4.2.P126.		1
1246	Genomics of Alzheimer's disease. , 2020, , 3-18.		0
1247	Efeito da suplementação de Ácido graxo ômega 3 isolado ou associado em pacientes com doença de Alzheimer: uma revisão sistemática da literatura científica. HU Revista, 2020, 45, 452-464.	0.3	1
1250	Symptomatic, Genetic, and Mechanistic Overlaps between Autism and Alzheimer's Disease. Biomolecules, 2021, 11, 1635.	1.8	16
1257	Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder?. American Journal of Cardiovascular Disease, 2013, 3, 197-226.	0.5	126
1260	Whether Alzheimer's disease related genes also differently express in the hippocampus of Ts65Dn mice?. International Journal of Clinical and Experimental Pathology, 2015, 8, 4120-5.	0.5	2
1261	Neural stem/progenitor cells in Alzheimer's disease. Yale Journal of Biology and Medicine, 2016, 89, 23-35.	0.2	47
1263	An insight into Alzheimer's disease and its on-setting novel genes. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	0.4	4
1264	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	4.9	203
1265	A mechanistic survey of Alzheimer's disease. Biophysical Chemistry, 2022, 281, 106735.	1.5	34
1266	The Greek Variant in APP Gene: The Phenotypic Spectrum of APP Mutations. International Journal of Molecular Sciences, 2021, 22, 12355.	1.8	1
1267	Microglia-Based Sex-Biased Neuropathology in Early-Stage Alzheimer's Disease Model Mice and the Potential Pharmacologic Efficacy of Dioscin. Cells, 2021, 10, 3261.	1.8	5
1268	Tea polyphenols improve the memory in aging ovariectomized rats by regulating brain glucose metabolism in vivo and in vitro. Journal of Functional Foods, 2021, 87, 104856.	1.6	7
1269	BACE1: A Key Regulator in Alzheimer's Disease Progression and Current Development of its Inhibitors. Current Neuropharmacology, 2022, 20, 1174-1193.	1.4	12
1271	Prevention of Age-Related Cognitive Impairment, Alzheimer's Disease, and Dementia. , 2021, , 3948-3956.		0

#	ARTICLE	IF	CITATIONS
1272	Challenge accepted: uncovering the role of rare genetic variants in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 3.	4.4	19
1273	Measuring heritable contributions to Alzheimer's disease: polygenic risk score analysis with twins. <i>Brain Communications</i> , 2022, 4, fcab308.	1.5	27
1274	Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease. <i>Neural Regeneration Research</i> , 2022, 17, 1666.	1.6	87
1276	Regulation of neuronal autophagy and the implications in neurodegenerative diseases. <i>Neurobiology of Disease</i> , 2022, 162, 105582.	2.1	23
1277	The Cause of Alzheimer's Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress. , 2022, 13, 37.		22
1279	Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 1-15.	1.2	4
1280	Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2022, 56, 5516-5531.	1.2	13
1281	Physiology and pharmacology of amyloid precursor protein. , 2022, 235, 108122.		33
1282	Insertion of the Icelandic Mutation (A673T) by Prime Editing: A Potential Preventive Treatment for Familial and Sporadic Alzheimer's Disease. <i>CRISPR Journal</i> , 2022, 5, 109-122.	1.4	13
1283	Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects. <i>Journal of Genetics</i> , 2018, 97, 625-648.	0.4	1
1284	Tau-PET imaging as a molecular modality for Alzheimer's disease. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 374-386.	1.0	0
1285	Neuronal KCNQ2/3 channels are recruited to lipid raft microdomains by palmitoylation of BACE1. <i>Journal of General Physiology</i> , 2022, 154, .	0.9	8
1286	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 2687-2698.	0.4	13
1287	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 306-318.	21.5	273
1288	Knockdown of Amyloid Precursor Protein: Biological Consequences and Clinical Opportunities. <i>Frontiers in Neuroscience</i> , 2022, 16, 835645.	1.4	10
1289	AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model. <i>EMBO Molecular Medicine</i> , 2022, 14, e09824.	3.3	13
1290	Novel approaches to increase synaptic resilience as potential treatments for Alzheimer's disease. <i>Seminars in Cell and Developmental Biology</i> , 2023, 139, 84-92.	2.3	7
1291	Metabolites of soil microorganisms modulate amyloid $\beta^2$ production in Alzheimer's neurons. <i>Scientific Reports</i> , 2022, 12, 2690.	1.6	2

#	ARTICLE	IF	CITATIONS
1292	Whole-genome sequencing reveals that variants in the Interleukin 18 Receptor Accessory Protein 3â€™UTR protect against ALS. <i>Nature Neuroscience</i> , 2022, 25, 433-445.	7.1	16
1293	Alzheimerâ€™s disease â€“ the journey of a healthy brain into organ failure. <i>Molecular Neurodegeneration</i> , 2022, 17, 18.	4.4	41
1294	Solving neurodegeneration: common mechanisms and strategies for new treatments. <i>Molecular Neurodegeneration</i> , 2022, 17, 23.	4.4	83
1295	Current Drug Targets in Alzheimerâ€™s Associated Memory Impairment: A Comprehensive Review. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 255-275.	0.8	4
1296	Rational design, synthesis and activities of hydroxylated chalcones as highly potent dual functional agents against Alzheimer's disease. <i>Bioorganic Chemistry</i> , 2022, 122, 105662.	2.0	6
1297	Application of CRISPR/Cas9 in Alzheimerâ€™s Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 803894.	1.4	17
1298	Sex-Specific Regulation of Î²-Secretase: A Novel Estrogen Response Element (ERE)-Dependent Mechanism in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2022, 42, 1154-1165.	1.7	6
1299	Genomics and Functional Genomics of Alzheimer's Disease. <i>Neurotherapeutics</i> , 2022, 19, 152-172.	2.1	26
1300	Î²-Secretase structure and activity are modified by alterations in its membrane localization and ambient environment. <i>Journal of Biochemistry</i> , 2022, 171, 253-256.	0.9	2
1301	Finding effective combinations of compounds to prevent Alzheimerâ€™s disease. <i>Neural Regeneration Research</i> , 2022, 17, 2450.	1.6	0
1302	PTPRD and DCC Are Novel BACE1 Substrates Differentially Expressed in Alzheimerâ€™s Disease: A Data Mining and Bioinformatics Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4568.	1.8	4
1312	Alzheimerâ€™s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint. <i>Frontiers in Neuroscience</i> , 2022, 16, 837390.	1.4	12
1313	Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2022, 79, 565.	4.5	11
1314	History in Perspective: The prime pathological players and role of phytochemicals in Alzheimerâ€™s disease. <i>IBRO Neuroscience Reports</i> , 2022, 12, 377-389.	0.7	10
1315	What contribution can genetics make to predict the risk of Alzheimer's disease?. <i>Revue Neurologique</i> , 2022, 178, 414-421.	0.6	6
1317	From cradle to grave: neurogenesis, neuroregeneration and neurodegeneration in Alzheimerâ€™s and Parkinsonâ€™s diseases. <i>Neural Regeneration Research</i> , 2022, 17, 2606.	1.6	17
1318	Genetics of Alzheimerâ€™s disease: an East Asian perspective. <i>Journal of Human Genetics</i> , 2023, 68, 115-124.	1.1	13
1319	Viellissement cÃ©rÃ©bral pathologique. , 2021, , 681-777.		0

#	ARTICLE	IF	CITATIONS
1320	Exploring the Involvement of the Amyloid Precursor Protein A673T Mutation against Amyloid Pathology and Alzheimer's Disease in Relation to Therapeutic Editing Tools. <i>Pharmaceutics</i> , 2022, 14, 1270.	2.0	2
1321	Mouse Models of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	50
1322	Genetics of Alzheimer Disease. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 852-871.	0.4	6
1323	A comprehensive computational perspective in drug discovery for Alzheimer's disease.. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, .	0.6	0
1324	Brain Amyloid- $\beta$ Accumulation in AD Mouse Models Modified by Their Altered Gene Expression in the Presence of Human apoE Isoforms Through Aging Process. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1325	<i>Polyrhachis vicina</i> Roger Alleviates Memory Impairment in a Rat Model of Alzheimer's Disease Through the EGR1/BACE1/APP Axis. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1857-1867.	1.7	3
1326	Shati/Nat8l Overexpression Improves Cognitive Decline by Upregulating Neuronal Trophic Factor in Alzheimer's Disease Model Mice. <i>Neurochemical Research</i> , 2022, 47, 2805-2814.	1.6	2
1327	An isogenic panel of <i>App</i> knock-in mouse models: Profiling $\beta$ -secretase inhibition and endosomal abnormalities. <i>Science Advances</i> , 2022, 8, .	4.7	6
1328	Amylin and Secretases in the Pathology and Treatment of Alzheimer's Disease. <i>Biomolecules</i> , 2022, 12, 996.	1.8	5
1329	Resolution exchange with tunneling for enhanced sampling of protein landscapes. <i>Physical Review E</i> , 2022, 106, .	0.8	1
1330	The Amyloid Cascade Hypothesis 2.0: On the Possibility of Once-in-a-Lifetime-Only Treatment for Prevention of Alzheimer's Disease and for Its Potential Cure at Symptomatic Stages. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 369-399.	1.2	6
1331	Current landscape of gene editing technology in biomedicine: Applications, advantages, challenges, and perspectives. <i>MedComm</i> , 2022, 3, .	3.1	2
1332	Study of Alzheimer's disease- and frontotemporal dementia-associated genes in the Cretan Aging Cohort. <i>Neurobiology of Aging</i> , 2023, 123, 111-128.	1.5	2
1333	The neuroprotective effects of oxygen therapy in Alzheimer's disease: a narrative review. <i>Neural Regeneration Research</i> , 2023, 18, 57.	1.6	10
1334	Polygenic resilience scores capture protective genetic effects for Alzheimer's disease. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	6
1335	If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. <i>PLoS Biology</i> , 2022, 20, e3001694.	2.6	67
1336	Intravenous treatment with a molecular chaperone designed against $\beta$ -amyloid toxicity improves Alzheimer's disease pathology in mouse models. <i>Molecular Therapy</i> , 2023, 31, 487-502.	3.7	16
1337	A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2022, 27, 5227-5234.	4.1	6

#	ARTICLE	IF	CITATIONS
1338	Impact of A2T and D23N mutations on C99 homodimer conformations. <i>Journal of Chemical Physics</i> , 2022, 157, 085102.	1.2	0
1339	Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8714.	1.8	14
1340	Basics of amyloid $\beta$ -protein in Alzheimer's disease. , 2022, , 73-89.		0
1341	Herpes Simplex Virus Infection Increases Beta-Amyloid Production and Induces the Development of Alzheimer's Disease. <i>BioMed Research International</i> , 2022, 2022, 1-11.	0.9	4
1342	Cannabinoids " a new therapeutic strategy in neurology. , 2022, 125, 349-355.		4
1343	Heads Up! Interlinked Amyloidogenic and Axonal Transport Pathways in Concussion-Induced Neurodegeneration. <i>Neuroscience Insights</i> , 2022, 17, 263310552211296.	0.9	0
1344	Menopause and development of Alzheimer's disease: Roles of neural glucose metabolism and Wnt signaling. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
1345	Ovariectomy-induced hormone deprivation aggravates $A\beta$ 1-42 deposition in the basolateral amygdala and cholinergic fiber loss in the cortex but not cognitive behavioral symptoms in a triple transgenic mouse model of Alzheimer's disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
1346	WINNER: A network biology tool for biomolecular characterization and prioritization. <i>Frontiers in Big Data</i> , 0, 5, .	1.8	2
1347	Aspartic Proteases of Alzheimer's Disease: $\beta$ - and $\gamma$ -Secretases. , 2016, , 950-959.		0
1348	Amyloid Cascade Hypothesis for the Treatment of Alzheimer's Disease: Progress and Challenges. , 2022, 13, 1745.		21
1349	A Review of CRISPR Cas9 for Alzheimer's Disease: Treatment Strategies and Could target APOE e4, APP, and PSEN-1 Gene using CRISPR cas9 Prevent the Patient from Alzheimer's Disease?. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 745-757.	0.1	1
1350	Physiological Roles of $\beta$ -amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology. <i>Neuroscience Bulletin</i> , 2023, 39, 1289-1308.	1.5	13
1351	BACE2: A Promising Neuroprotective Candidate for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2023, 94, S159-S171.	1.2	2
1352	Role of Hydrophobicity at the N-Terminal Region of $A\beta$ 42 in Secondary Nucleation. <i>ACS Chemical Neuroscience</i> , 2022, 13, 3477-3487.	1.7	1
1354	Rare Amyloid Precursor Protein Point Mutations Recapitulate Worldwide Migration and Admixture in Healthy Individuals: Implications for the Study of Neurodegeneration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15871.	1.8	3
1356	Accumulation of amyloid- $\beta$ in the brain of mouse models of Alzheimer's disease is modified by altered gene expression in the presence of human apoE isoforms during aging. <i>Neurobiology of Aging</i> , 2023, 123, 63-74.	1.5	2
1358	Experimental approaches for altering the expression of Abeta-degrading enzymes. <i>Journal of Neurochemistry</i> , 2023, 164, 725-763.	2.1	4

#	ARTICLE	IF	CITATIONS
1360	The Binding of Different Substrate Molecules at the Docking Site and the Active Site of $\beta$ -Secretase Can Trigger Toxic Events in Sporadic and Familial Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1835.	1.8	2
1361	$A\beta$ 242 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	3
1362	The neuroimmune axis of Alzheimer's disease. <i>Genome Medicine</i> , 2023, 15, .	3.6	59
1363	The Pursuit of the "Inside" of the Amyloid Hypothesis: Is C99 a Promising Therapeutic Target for Alzheimer's Disease?. <i>Cells</i> , 2023, 12, 454.	1.8	3
1364	The Amyloid Cascade Hypothesis 2.0: Generalization of the Concept. <i>Journal of Alzheimer's Disease Reports</i> , 2023, 7, 21-35.	1.2	4
1365	Age-dependent NMDA receptor function is regulated by the amyloid precursor protein. <i>Aging Cell</i> , 2023, 22, .	3.0	6
1367	Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease. <i>Neuropharmacology</i> , 2023, 229, 109478.	2.0	10
1368	Prime Editing for Human Gene Therapy: Where Are We Now?. <i>Cells</i> , 2023, 12, 536.	1.8	11
1369	Multifactorial glial responses and their contributions to Alzheimer's disease continuum. <i>Clinical and Experimental Neuroimmunology</i> , 2023, 14, 82-91.	0.5	1
1370	The Alzheimer's Disease Mitochondrial Cascade Hypothesis: A Current Overview. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 751-768.	1.2	19
1371	Specific Mutations near the Amyloid Precursor Protein Cleavage Site Increase $\beta$ -Secretase Sensitivity and Modulate Amyloid- $\beta$ Production. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3970.	1.8	6
1373	How Single Site Mutations Can Help Understanding Structure Formation of Amyloid $\beta$ . <i>Macromolecular Bioscience</i> , 2023, 23, .	2.1	3
1374	The complex genetic architecture of Alzheimer's disease: novel insights and future directions. <i>EBioMedicine</i> , 2023, 90, 104511.	2.7	41
1376	New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5383.	1.8	7
1377	The $\beta$ -secretase-derived APP fragment $\beta$ -CTF is localized in Golgi, endosomes and extracellular vesicles and contributes to $A\beta$ production. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	2.4	4
1378	Identification and characterization of bioactive peptides from marine crustacean crabs: a possible drug candidate for Alzheimer's disease. <i>Aquaculture International</i> , 2023, 31, 2221-2234.	1.1	2
1379	Lowering levels of reelin in entorhinal cortex layer II-neurons results in lowered levels of intracellular amyloid- $\beta$ . <i>Brain Communications</i> , 2023, 5, .	1.5	3
1380	E674Q (Shanghai APP mutant), a novel amyloid precursor protein mutation, in familial late-onset Alzheimer's disease. <i>Genes and Diseases</i> , 2024, 11, 1022-1034.	1.5	1



#	ARTICLE	IF	CITATIONS
1381	Accelerated long-term forgetting: A sensitive paradigm for detecting subtle cognitive impairment and evaluating BACE1 inhibitor efficacy in preclinical Alzheimer's disease. , 0, 2, .		1
1387	Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia. Nature Aging, 2023, 3, 494-505.	5.3	13
1395	Amyloid $\beta$ -based therapy for Alzheimer's disease: challenges, successes and future. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	49
1401	Detection and treatment of Alzheimer's disease in its preclinical stage. Nature Aging, 2023, 3, 520-531.	5.3	12
1402	Applications of fMRI to Neurodegenerative Disease. , 2023, , 819-860.		0
1405	Is the Persistence of the Amyloid Cascade Hypothesis a Result of Constant Confirmation Bias?. , 2023, , 451-469.		0
1406	Alzheimer's Research Gains Momentum and Spreads Out. , 2023, , 285-307.		0
1408	Pathological Roles of INPP5D in Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2023, , 289-301.	0.8	0
1410	Rhombomere 1 r1. , 2023, , 391-436.		0
1411	Neurogenetic motor disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 183-250.	1.0	0
1416	Emerging diagnostics and therapeutics for Alzheimer disease. Nature Medicine, 2023, 29, 2187-2199.	15.2	20